1er juillet

Lancet Diab Endocrinol https://www.thelancet.com/journals/landia/home

• 00:00
  [Correspondence] An integrated diabetes and mental health intervention for people with type 1 diabetes and severe disordered eating: a prospective proof-of-concept cohort study - Khalida Ismail, Diane Turner, Jennie Brown, Miranda Rosenthal, Salma Ayis, Nick Oliver, Yuk-Fun Liu, Amy Harrison, Chris Garrett, David Hopkins, Janet Treasure, Jonathan Valabhji, Stephen Thomas, Marietta Stadler Lancet Diab Endocrinol
  Disordered eating is a phenomenon that affects approximately 30% of people with type 1 diabetes, and is characterised by omission of some amount of insulin secondary to fear of weight gain.1,2 Depending on the dose and type of insulin omitted, the subsequent persistent hyperglycaemia, polyuria, (…) (The Lancet Diabetes & Endocrinology 12, 7 (2024))

7 juin

Lancet Diab Endocrinol https://www.thelancet.com/journals/landia/home

• 00:30
  [Editorial] Alarming rise in young-onset type 2 diabetes - The Lancet Diabetes & Endocrinology Lancet Diab Endocrinol
  A new report by Diabetes UK, published in May, 2024, showed an almost 40% increase in 5 years in the number of people diagnosed with type 2 diabetes in the UK who were younger than 40 years (between 2016–17 and 2022–23). On a global level, according to data from the 10th edition of the Diabetes (…) (The Lancet Diabetes & Endocrinology 12, 7 (2024))

4 juin

Lancet Diab Endocrinol https://www.thelancet.com/journals/landia/home

• 00:30
  [Articles] Associations between BMI and hospital resource use in patients hospitalised for COVID-19 in England: a community-based cohort study - James Altunkaya, Carmen Piernas, Koen B Pouwels, Susan A Jebb, Philip Clarke, Nerys M Astbury, Jose Leal Lancet Diab Endocrinol
  Patients admitted to hospital with COVID-19 with a BMI above the healthy range had longer stays, were more likely to be admitted to ICU, and had higher health-care costs associated with hospital treatment of COVID-19 infection as a result. This information can inform national resource allocation (…) (The Lancet Diabetes & Endocrinology 12, 7 (2024))
• 00:30
  [Comment] Association between BMI and COVID-19 on hospital budgets - Maya Nitecki, Arnon Afek, Gilad Twig Lancet Diab Endocrinol
  Excessive weight has been causally linked with some types of cancer, type 2 diabetes, cardiovascular morbidity, and other non-communicable chronic diseases.1 By 2035, it is estimated that 1·4 billion adults will be living with obesity globally and the global economic impact will be US$4·32 (…) (The Lancet Diabetes & Endocrinology 12, 7 (2024))

1er juin

Lancet Diab Endocrinol https://www.thelancet.com/journals/landia/home

• 00:00
  [Personal View] Small Island Developing States: addressing the intersecting challenges of non-communicable diseases, food insecurity, and climate change - Cornelia Guell, Arlette Saint Ville, Simon G Anderson, Madhuvanti M Murphy, Viliamu Iese, Sashi Kiran, Gordon M Hickey, Nigel Unwin Lancet Diab Endocrinol
  Small Island Developing States (SIDS) include 37 UN member countries sharing economic, environmental, and social vulnerabilities and intractable health challenges. In over 80% of SIDS, more than one in six adults die prematurely from a non-communicable disease (NCD), with poor diet being a major (…) (The Lancet Diabetes & Endocrinology 12, 6 (2024))
• 00:00
  [Comment] Perfluoroalkyl and polyfluoroalkyl substances: the price of forever chemicals - Dana L Sheinhaus, Andrea C Gore Lancet Diab Endocrinol
  The past seven decades have ushered in technology intended to make our lives easier, including innovations such as non-stick cookware, waterproof raincoats, and abundant hair and skincare products; however, these and other consumer products can contain endocrine-disrupting chemicals (EDCs), (…) (The Lancet Diabetes & Endocrinology 12, 6 (2024))

31 mai

Lancet Diab Endocrinol https://www.thelancet.com/journals/landia/home

• 00:30
  [Review] Causes, prevention, and management of diabetes-related foot ulcers - William Jeffcoate, Edward J Boyko, Fran Game, Prue Cowled, Eric Senneville, Robert Fitridge Lancet Diab Endocrinol
  In this Review, we aim to complement the 2023 update of the guidelines of the International Working Group on the Diabetic Foot. We highlight the complexity of the pathological processes that underlie diabetes-related foot ulceration (DFU) and draw attention to the potential implications for (…) (The Lancet Diabetes & Endocrinology 12, 7 (2024))
• 00:30
  [Correspondence] Lack of access to insulin: undermining the Rights of the Child - Olivia Heller, Olivier Duperrex, Philip D Jaffé, Jeffrey Goldhagen, Carol A Abidha, Ann Skelton, Mikiko Otani, Yvon Heller, Jean-Dominique Vassalli, David Beran Lancet Diab Endocrinol
  2024 marks the centenary of the League of Nations' Declaration of the Rights of the Child. The Geneva Declaration highlighted the health needs of children and proclaimed the duty of governments to respond to these needs.1 Its influence led to the adoption of the 1989 Convention on the Rights of (…) (The Lancet Diabetes & Endocrinology 12, 7 (2024))
• 00:30
  [Comment] Diabetes distress: the psychological burden of living with diabetes - Lydia Poole, Ruth A Hackett Lancet Diab Endocrinol
  Living with type 1 or type 2 diabetes requires patient's sustained engagement with multiple self-care behaviours including medication taking, healthy eating, and glucose monitoring. The ongoing demands of self-care coupled with a fear of complications takes a toll on these individuals. Diabetes (…) (The Lancet Diabetes & Endocrinology 12, 7 (2024))

28 mai

Lancet Diab Endocrinol https://www.thelancet.com/journals/landia/home

• 00:30
  [Personal View] Advancing diabetes surveillance ecosystems: a case study of India - Jithin Sam Varghese, Emily N Peterson, Mohammed K Ali, Nikhil Tandon Lancet Diab Endocrinol
  Professional society and expert guidelines recommend the achievement of glycaemic, blood pressure, and cholesterol targets to prevent the microvascular and macrovascular complications of diabetes. The WHO Diabetes Compact recommends that countries meet and monitor these targets for diabetes (…) (The Lancet Diabetes & Endocrinology 12, 7 (2024))

24 mai

Lancet Diab Endocrinol https://www.thelancet.com/journals/landia/home

• 00:30
  [Personal View] Prediction of progression to type 1 diabetes with dynamic biomarkers and risk scores - Mugdha V Joglekar, Simranjeet Kaur, Flemming Pociot, Anandwardhan A Hardikar Lancet Diab Endocrinol
  Identifying biomarkers of functional ?-cell loss is an important step in the risk stratification of type 1 diabetes. Genetic risk scores (GRS), generated by profiling an array of single nucleotide polymorphisms, are a widely used type 1 diabetes risk-prediction tool. Type 1 diabetes screening (…) (The Lancet Diabetes & Endocrinology 12, 7 (2024))

23 mai

Lancet Diab Endocrinol https://www.thelancet.com/journals/landia/home

• 00:30
  [Comment] Measuring serum testosterone in women - David J Handelsman, Susan R Davis Lancet Diab Endocrinol
  When requesting a blood testosterone test in women it is key to be aware of the limitations of the commercial immunoassays used by most pathology laboratories. Major limitations of reported low blood testosterone concentrations in women must be recognised before deciding whether the result is a (…) (The Lancet Diabetes & Endocrinology 12, 7 (2024))

21 mai

Lancet Diab Endocrinol https://www.thelancet.com/journals/landia/home

• 00:30
  [In Focus] The ongoing quest for worldwide iodine sufficiency - Ray Cavanaugh Lancet Diab Endocrinol
  People in the USA these days rarely think about goitres and iodine deficiency. However, these were very much issues in the country until about a century ago. Drastic improvement began to take place on May 1, 1924, when iodised salt first appeared in US grocery stores. Largely due to this (…) (The Lancet Diabetes & Endocrinology 12, 7 (2024))

18 mai

Lancet Diab Endocrinol https://www.thelancet.com/journals/landia/home

• 00:30
  [Articles] Effect of SGLT2 inhibitors on heart failure outcomes and cardiovascular death across the cardiometabolic disease spectrum: a systematic review and meta-analysis - Muhammad Shariq Usman, Deepak L Bhatt, Ishaque Hameed, Stefan D Anker, Alice Y Y Cheng, Adrian F Hernandez, William Schuyler Jones, Muhammad Shahzeb Khan, Mark C Petrie, Jacob A Udell, Tim Friede, Javed Butler Lancet Diab Endocrinol
  SGLT2 inhibitors reduced heart failure events and cardiovascular death in patients with heart failure, type 2 diabetes, chronic kidney disease, and atherosclerotic cardiovascular disease. These effects were consistent across a wide range of subgroups within these populations. This supports the (…) (The Lancet Diabetes & Endocrinology 12, 7 (2024))
• 00:30
  [Comment] SGLT2 inhibitors in clinical practice - Lars Rydén, Anna Norhammar Lancet Diab Endocrinol
  On Sept 15, 2015, in Stockholm, the attendees at the Congress of the European Association for the Study of Diabetes were stunned by the presentation of the first randomised investigation of a sodium–glucose co-transporter-2 (SGLT2) inhibitor, empagliflozin, in the EMPA-REG OUTCOME trial1 in (…) (The Lancet Diabetes & Endocrinology 12, 7 (2024))

11 mai

Lancet Diab Endocrinol https://www.thelancet.com/journals/landia/home

• 00:30
  [Editorial] Sleep: a neglected public health issue - The Lancet Diabetes & Endocrinology Lancet Diab Endocrinol
  Controlled by circadian rhythms and sleep–wake homeostasis, sleep is a state of reduced mental and physical activity—a time for body and mind to recharge in preparation for the next day. Although adults aged 18 years and older are recommended to get 7–9 h of sleep per day (and children up to 12 (…) (The Lancet Diabetes & Endocrinology 12, 6 (2024))

7 mai

Lancet Diab Endocrinol https://www.thelancet.com/journals/landia/home

• 00:30
  [Review] Sex, race, and BMI in clinical trials of medications for obesity over the past three decades: a systematic review - Moath S Alsaqaaby, Sarah Cooney, Carel W le Roux, Dimitri J Pournaras Lancet Diab Endocrinol
  Medications for obesity have been studied in various populations over the past three decades. We aimed to quantify the baseline demographic characteristics of BMI, sex, age, and race in randomised clinical trials (RCTs) across three decades to establish whether the population studied is (…) (The Lancet Diabetes & Endocrinology 12, 6 (2024))
• 00:30
  [Corrections] Correction to Lancet Diabetes Endocrinol 2024; 12: 233–46 Lancet Diab Endocrinol
  Michael EJ Lean, Wilma S Leslie, Alison C Barnes et al. 5-year follow-up of the randomised Diabetes Remission Clinical Trial (DiRECT) of continued support for weight loss maintenance in the UK: an extension study. Lancet Diabetes Endocrinol 2024; 12: 233–46—In this Article in Figure 1, some of (…) (The Lancet Diabetes & Endocrinology 12, 6 (2024))
• 00:30
  [Correspondence] Effect of population-wide screening for presymptomatic early-stage type 1 diabetes on paediatric clinical care - Ezio Bonifacio, Christiane Winkler, Peter Achenbach, Anette-Gabriele Ziegler Lancet Diab Endocrinol
  Population-wide screening of children for presymptomatic early-stage type 1 diabetes is gaining momentum. Studies have demonstrated feasibility and acceptance, and shown that the rate of progression to clinical stage 3 diabetes is similar if islet autoantibody-positive early-stage type 1 (…) (The Lancet Diabetes & Endocrinology 12, 6 (2024))
• 00:30
  [Corrections] Correction to Lancet Diabetes Endocrinol 2024; 12: 301–02 Lancet Diab Endocrinol
  Flint SW. Rethinking the label “Anti-Obesity Medication”. Lancet Diabetes Endocrinol 2024; 12: 301–02—In this Correspondence, line three of paragraph four should have said “metabotherapy”. This correction has been made to the online version as of May 6, 2024. (The Lancet Diabetes & Endocrinology 12, 6 (2024))

4 mai

Lancet Diab Endocrinol https://www.thelancet.com/journals/landia/home

• 00:30
  [Articles] Use of melatonin supplements and risk of type 2 diabetes and cardiovascular diseases in the USA: insights from three prospective cohort studies - Yanping Li, Tianyi Huang, Susan Redline, Walter C Willett, JoAnn E Manson, Eva S Schernhammer, Frank B Hu Lancet Diab Endocrinol
  With up to 23 years of follow-up of three large prospective cohorts of middle-aged and older men and women, self-reported melatonin supplement use was not associated with risk of type 2 diabetes or cardiovascular disease. Further research is warranted to assess if melatonin supplement use could (…) (The Lancet Diabetes & Endocrinology 12, 6 (2024))
• 00:30
  [Comment] Melatonin: is it really a cardiovascular wonder pill for shift workers? - Pei Xue, Diana A Nôga, Christian Benedict Lancet Diab Endocrinol
  Melatonin, a hormone primarily produced by the brain's pineal gland, is typically secreted during darkness, aligning with the time when most people sleep. Melatonin plays a crucial part in signalling the onset of the biological night. It achieves this through multiple mechanisms, including (…) (The Lancet Diabetes & Endocrinology 12, 6 (2024))

1er mai

Lancet Diab Endocrinol https://www.thelancet.com/journals/landia/home

• 00:00
  [Comment] Food additive emulsifiers: a new risk factor for type 2 diabetes? - Mengxi Du, Frank B Hu Lancet Diab Endocrinol
  Type 2 diabetes is a major public health concern globally. Recent estimates reveal that more than 529 million people worldwide are living with diabetes (>90% have type 2 diabetes), with a projection of 1·31 billion cases by 2050.1 Although the causes of type 2 diabetes are multifaceted, (...) (The Lancet Diabetes & Endocrinology 12, 5 (2024))
• 00:00
  [Correspondence] Vitamin D supplements and future fracture risk among Mongolian schoolchildren – Author's reply - Adrian R Martineau, Polyna Khudyakov, Davaasambuu Ganmaa Lancet Diab Endocrinol
  We thank Ning Ma and colleagues for their comments on our work.1 With regard to ethics, our protocol was reviewed and approved by institutional review boards in both Mongolia and the USA, and the trial was monitored by an external data and safety monitoring board whose members were independent (...) (The Lancet Diabetes & Endocrinology 12, 5 (2024))
• 00:00
  [Correspondence] Rethinking the label anti-obesity medication - Stuart W Flint Lancet Diab Endocrinol
  Pharmacotherapy approved to support people living with obesity has received much attention from the scientific and clinical communities, and general public. Clinical trials have reported substantial effects of these medications, including weight reduction and a reduced risk of cardiac events (...) (The Lancet Diabetes & Endocrinology 12, 5 (2024))
• 00:00
  [Correspondence] Environmental chemical obesogens, what can we do? - Tim Lobstein Lancet Diab Endocrinol
  Virtually every country in the world has shown a dramatic increase in the prevalence of overweight and obesity since the 1980s. Rapidly changing dietary patterns, reductions in physical activity, and increased sedentary behaviour are assumed to be the main drivers of this rising trend, but (...) (The Lancet Diabetes & Endocrinology 12, 5 (2024))
• 00:00
  [In Focus] Anand Hardikar: a scientific nomad searching for the truth - Susan Rahimi, Marta Koch Lancet Diab Endocrinol
  Drawing inspiration and ideas from other fields is something Anandwardhan (Anand) Awadhoot Hardikar is passionate about. “Every successful researcher needs to have an open mind about what is around them”, says Anand. Whether it's utilising game theory or bird migration patterns in his own (...) (The Lancet Diabetes & Endocrinology 12, 5 (2024))
• 00:00
  [Comment] The Human Insulin Thermal Solution project—a private sector initiative to address the thermostability of insulin - Mats Rasmussen, Morten Hach, Jørgen Iwersen, Gayathri Anil, Henrik Rosborg, Jens Larsen, Lise Camilla Hoffmann, Peter Kurtzhals Lancet Diab Endocrinol
  Insulin products should be refrigerated at 2–8°C before first use and can be stored at ambient temperatures (ie, 25–30°C) after opening for 4–6 weeks, as recommended by insulin manufacturers. The rate of physical and chemical degradation of insulin increases when the temperature is increased. (...) (The Lancet Diabetes & Endocrinology 12, 5 (2024))
• 00:00
  [Comment] Endpoints for clinical trials in type 1 diabetes drug development - Alfonso Galderisi, Brynn E Marks, Linda A DiMeglio, Carine de Beaufort Lancet Diab Endocrinol
  Type 1 diabetes is characterised by substantial disease heterogeneity which influences rates of progression during presymptomatic stages, age at clinical onset, and residual ?-cell function at the time of detectable autoimmunity. This heterogeneity poses challenges for disease staging and (...) (The Lancet Diabetes & Endocrinology 12, 5 (2024))
• 00:00
  [Correspondence] Vitamin D supplements and future fracture risk among Mongolian schoolchildren - Ning Ma, Xia Cui, Wenquan Niu Lancet Diab Endocrinol
  We read with great interest the study by Ganmaa and colleagues,1 who examined the effect of vitamin D supplements on 3-year fracture risk among 11 475 Mongolian schoolchildren aged 6–13 years. We commend Ganmaa and colleagues1 for providing solid, albeit statistically insignificant, data from (...) (The Lancet Diabetes & Endocrinology 12, 5 (2024))
• 00:00
  [Articles] Food additive emulsifiers and the risk of type 2 diabetes: analysis of data from the NutriNet-Santé prospective cohort study - Clara Salame, Guillaume Javaux, Laury Sellem, Emilie Viennois, Fabien Szabo de Edelenyi, Cédric Agaësse, Alexandre De Sa, Inge Huybrechts, Fabrice Pierre, Xavier Coumoul, Chantal Julia, Emmanuelle Kesse-Guyot, Benjamin Allès, Léopold K Fezeu, Serge Hercberg, Mélanie Deschasaux-Tanguy, Emmanuel Cosson, Sopio Tatulashvili, Benoit Chassaing, Bernard Srour, Mathilde Touvier Lancet Diab Endocrinol
  We found direct associations between the risk of type 2 diabetes and exposures to various food additive emulsifiers widely used in industrial foods, in a large prospective cohort of French adults. Further research is needed to prompt re-evaluation of regulations governing the use of additive (...) (The Lancet Diabetes & Endocrinology 12, 5 (2024))

30 avril

Lancet Diab Endocrinol https://www.thelancet.com/journals/landia/home

• 00:30
  [Articles] Comparing advanced hybrid closed loop therapy and standard insulin therapy in pregnant women with type 1 diabetes (CRISTAL): a parallel-group, open-label, randomised controlled trial - Katrien Benhalima, Kaat Beunen, Nancy Van Wilder, Dominique Ballaux, Gerd Vanhaverbeke, Youri Taes, Xavier-Philippe Aers, Frank Nobels, Joke Marlier, Dahae Lee, Joke Cuypers, Vanessa Preumont, Sarah E Siegelaar, Rebecca C Painter, Annouschka Laenen, Pieter Gillard, Chantal Mathieu Lancet Diab Endocrinol
  In pregnant women starting with tighter glycaemic control, AHCL therapy did not improve overall time in target range but improved overnight time in target range, reduced time below range, and improved treatment satisfaction. These data suggest that the MiniMed 780G can be safely used in (…) (The Lancet Diabetes & Endocrinology 12, 6 (2024))
• 00:30
  [Comment] Demarcating the benefits of hybrid closed loop therapy in pregnant women with type 1 diabetes - Helen R Murphy, Eleanor M Scott Lancet Diab Endocrinol
  The role of hybrid closed-loop systems in the clinical management of type 1 diabetes is rapidly expanding. Randomised controlled trials have shown life-changing clinical and quality-of-life benefits beyond those that can be obtained by use of continuous glucose monitoring (CGM) with an insulin (…) (The Lancet Diabetes & Endocrinology 12, 6 (2024))
• 00:30
  [Comment] Setmelanotide: new promise for the treatment of hypothalamic obesity? - Manuel Tena-Sempere Lancet Diab Endocrinol
  With the increase in obesity prevalence worldwide, considerable efforts have been made to investigate the molecular and neurohormonal mechanisms of bodyweight control, as a means to identify novel therapeutic targets. As a paradigmatic example, characterisation of the physiological actions of (…) (The Lancet Diabetes & Endocrinology 12, 6 (2024))
• 00:30
  [Articles] Setmelanotide for the treatment of acquired hypothalamic obesity: a phase 2, open-label, multicentre trial - Christian L Roth, Cecilia Scimia, Ashley H Shoemaker, Michael Gottschalk, Jennifer Miller, Guojun Yuan, Sonali Malhotra, M Jennifer Abuzzahab Lancet Diab Endocrinol
  These findings support setmelanotide as a novel effective treatment of hypothalamic obesity. (The Lancet Diabetes & Endocrinology 12, 6 (2024))

25 avril

Lancet Diab Endocrinol https://www.thelancet.com/journals/landia/home

• 00:30
  [Comment] Bone mineral density as a surrogate endpoint for fracture risk reduction in clinical trials of osteoporosis therapies: an update on SABRE - Dennis M Black, Austin R Thompson, Richard Eastell, Mary L Bouxsein Lancet Diab Endocrinol
  Launched as a public–private partnership funded by the Foundation for the National Institutes of Health, the Study to Advance Bone Mineral Density as a Regulatory Endpoint (SABRE) aims to change the framework for how clinical trials of new anti-osteoporosis drugs are conducted, to promote (…) (The Lancet Diabetes & Endocrinology 12, 6 (2024))

20 avril

Lancet Diab Endocrinol https://www.thelancet.com/journals/landia/home

• 00:30
  [Editorial] Earth Day: time for transformational change - The Lancet Diabetes & Endocrinology Lancet Diab Endocrinol
  On April 22, the 54th annual Earth Day will continue endeavours to “diversify, educate and activate the environmental movement worldwide”. Part of Earth Day's ongoing work includes broadening the definition of environmental issues to include the health of both individuals and communities. This (...) (The Lancet Diabetes & Endocrinology 12, 5 (2024))

18 avril

Lancet Diab Endocrinol https://www.thelancet.com/journals/landia/home

• 00:30
  [Correspondence] Improving support for university students with type 1 diabetes - Gijsbert Stoet, Emily Foster, Catherine Kerr, Lingqing Jiang, Megan-Ann Thornhill, Katarzyna Cyranka, Bart?omiej Matejko, Dominika Sarna-Palacz, Magdalena P?onka-St?pie?, Tomasz Klupa Lancet Diab Endocrinol
  Using prevalence data from the UK,1 we estimate that there are more than 10 000 university students with type 1 diabetes, out of a total student population of 2·8 million. (The Lancet Diabetes & Endocrinology 12, 6 (2024))

9 avril

Lancet Diab Endocrinol https://www.thelancet.com/journals/landia/home

• 00:30
  [Review] Endocrine health in survivors of adult-onset cancer - Cornelia S Link-Rachner, Andy Göbel, Nikolai P Jaschke, Tilman D Rachner Lancet Diab Endocrinol
  Long-term survivors of cancer (ie, the patient who is considered cured or for whom the disease is under long-term control and unlikely to recur) are at an increased risk of developing endocrine complications such as hypothalamic–pituitary dysfunctions, hypogonadisms, osteoporosis, or metabolic (...) (The Lancet Diabetes & Endocrinology 12, 5 (2024))

6 avril

Lancet Diab Endocrinol https://www.thelancet.com/journals/landia/home

• 00:30
  [Comment] Glycaemic index as part of the diabetes prevention strategy - Gary Frost Lancet Diab Endocrinol
  The study by Victoria Miller and colleagues1 in The Lancet Diabetes & Endocrinology adds to and extends the growing body of evidence of the importance of understanding the physiological effect of dietary carbohydrate on homeostatic systems as a driver for the risk of non-communicable (...) (The Lancet Diabetes & Endocrinology 12, 5 (2024))
• 00:30
  [In Focus] Direct-to-consumer services: improving access to care for people with diabetes and obesity - Talha Burki Lancet Diab Endocrinol
  When Eli Lilly started its US direct-to-consumer service earlier this year, it did so with the stated aim of offering “patients an innovative end-to-end experience to manage their health and access their medicines”. LillyDirect's initial focus is on diabetes, migraine, and obesity, although (...) (The Lancet Diabetes & Endocrinology 12, 5 (2024))
• 00:30
  [Articles] Associations of the glycaemic index and the glycaemic load with risk of type 2 diabetes in 127 594 people from 20 countries (PURE): a prospective cohort study - Victoria Miller, David A Jenkins, Mahshid Dehghan, Kristie Srichaikul, Sumathy Rangarajan, Andrew Mente, Viswanathan Mohan, Sumathi Swaminathan, Rosnah Ismail, Maria Luz Diaz, Rekha M Ravindran, Katarzyna Zatonska, Ahmad Bahonar, Yuksel Altuntas, Rasha Khatib, Patricio Lopez-Jaramillo, Afzalhussein Yusufali, Karen Yeates, Jephat Chifamba, Romaina Iqbal, Rita Yusuf, Elizabeth Catherina Swart, Hu Bo, Guoliang Han, Xiaocong Li, Khalid F Alhabib, Annika Rosengren, Alvaro Avezum, Fernando Lanas, Salim Yusuf, Prospective Urban and Rural Epidemiology (PURE) study investigators Lancet Diab Endocrinol
  Diets with a high glycaemic index and a high glycaemic load were associated with a higher risk of incident type 2 diabetes in a multinational cohort spanning five continents. Our findings suggest that consuming low glycaemic index and low glycaemic load diets might prevent the development of (...) (The Lancet Diabetes & Endocrinology 12, 5 (2024))

1er avril

Lancet Diab Endocrinol https://www.thelancet.com/journals/landia/home

• 00:00
  [Correspondence] Evaluating the effect of bempedoic acid on kidney function: call for cautious implementation - Dion Groothof, Stephan J L Bakker Lancet Diab Endocrinol
  We read with interest the Article by Ray and colleagues,1 which showed that bempedoic acid compared with placebo reduced the risk of cardiovascular events in statin-intolerant patients with type 2 diabetes without previous atherosclerotic cardiovascular disease. They also showed (...) (The Lancet Diabetes & Endocrinology 12, 4 (2024))
• 00:00
  [Correspondence] Evaluating the effect of bempedoic acid on kidney function: call for cautious implementation – Authors' reply - Kausik K Ray, LeAnne Bloedon, Na Li, Steven E Nissen, on behalf of the co-authors Lancet Diab Endocrinol
  We thank Groothof and Bakker for their query and the opportunity to offer clarification. There are extensive published data on the safety of bempedoic acid from the CLEAR Outcomes trial, in which 13 970 statin-intolerant patients at high cardiovascular risk received bempedoic acid.1,2 The (...) (The Lancet Diabetes & Endocrinology 12, 4 (2024))
• 00:00
  [Correspondence] Bridging the worlds of research and policy making - Jonathan Valabhji Lancet Diab Endocrinol
  The first Editorial of 2024 in The Lancet Diabetes & Endocrinology was entitled “From research to policy: still a long way to go”.1 It explored potential reasons why much research in the field, despite its transformative potential for impact, is not taken up and implemented into health (...) (The Lancet Diabetes & Endocrinology 12, 4 (2024))
• 00:00
  [Personal View] Tight versus liberal blood-glucose control in the intensive care unit: special considerations for patients with diabetes - Christian von Loeffelholz, Andreas L Birkenfeld Lancet Diab Endocrinol
  Stress hyperglycaemia, hypoglycaemia, and diabetes are common in critically ill patients and related to clinical endpoints. To avoid complications related to hypoglycaemia and hyperglycaemia, it is recommended to start insulin therapy for the majority of critically ill patients with persistent (...) (The Lancet Diabetes & Endocrinology 12, 4 (2024))

30 mars

Lancet Diab Endocrinol https://www.thelancet.com/journals/landia/home

• 00:30
  [Comment] Type 1 diabetes: heterogeneity in heritability - Richard David Leslie Lancet Diab Endocrinol
  Clinical features can categorically define a disease, but that is not true for type 1 diabetes. Recognised as a severe childhood-onset disease often presenting with diabetic ketoacidosis, with children depending on insulin for survival, type 1 diabetes is now understood to be predominantly an (...) (The Lancet Diabetes & Endocrinology 12, 5 (2024))
• 00:30
  [Articles] Familial aggregation and heritability of childhood-onset and adult-onset type 1 diabetes: a Swedish register-based cohort study - Yuxia Wei, Shengxin Liu, Tomas Andersson, Maria Feychting, Ralf Kuja-Halkola, Sofia Carlsson Lancet Diab Endocrinol
  Adult-onset type 1 diabetes seems to have weaker familial aggregation and lower heritability than childhood-onset type 1 diabetes. This finding suggests a larger contribution of environmental factors to the development of type 1 diabetes in adults than in children and highlights the need to (...) (The Lancet Diabetes & Endocrinology 12, 5 (2024))

28 mars

Lancet Diab Endocrinol https://www.thelancet.com/journals/landia/home

• 00:30
  [Articles] Effects of statin therapy on diagnoses of new-onset diabetes and worsening glycaemia in large-scale randomised blinded statin trials: an individual participant data meta-analysis - Cholesterol Treatment Trialists’ (CTT) Collaboration Lancet Diab Endocrinol
  Statins cause a moderate dose-dependent increase in new diagnoses of diabetes that is consistent with a small upwards shift in glycaemia, with the majority of new diagnoses of diabetes occurring in people with baseline glycaemic markers that are close to the diagnostic threshold for diabetes. (...) (The Lancet Diabetes & Endocrinology 12, 5 (2024))
• 00:30
  [Comment] How clinically relevant is statin-induced diabetes? - Hertzel C Gerstein, Marie Pigeyre Lancet Diab Endocrinol
  Diabetes is a common chronic disease that affects up to 10% of adults worldwide.1 People with diabetes are at high risk for a wide variety of serious health consequences including, but not limited to, myocardial infarctions, strokes, heart failure, blindness, kidney failure, lower limb (...) (The Lancet Diabetes & Endocrinology 12, 5 (2024))

23 mars

Lancet Diab Endocrinol https://www.thelancet.com/journals/landia/home

• 00:30
  [Comment] Disparities in fragility fracture and osteoporosis care in Africa - Kate A Ward, Tafadzwa Madanhire, Kebba Marenah, Lisa K Micklesfield, Celia L Gregson Lancet Diab Endocrinol
  Over the coming decades, Africa is predicted to have the greatest increase in the number of older people worldwide. Older people in this region spend longer living with disability and dependence than do those in high-income settings, affecting individuals, families, communities, and (...) (The Lancet Diabetes & Endocrinology 12, 5 (2024))

7 mars

Lancet Diab Endocrinol https://www.thelancet.com/journals/landia/home

• 00:30
  [Editorial] Undiagnosed type 2 diabetes: an invisible risk factor - The Lancet Diabetes & Endocrinology Lancet Diab Endocrinol
  There are diseases that puzzle doctors. Patients with these diseases often remain undiagnosed for years and some will die without an accurate diagnosis. The diagnosis of patients with mysterious diseases, many of which are rare diseases, can entail a long, complex, and detailed process that (...) (The Lancet Diabetes & Endocrinology 12, 4 (2024))

5 mars

Lancet Diab Endocrinol https://www.thelancet.com/journals/landia/home

• 00:30
  [Comment] Optimising zoledronate treatment holiday duration without loss of fracture prevention - Matthew T Drake Lancet Diab Endocrinol
  Osteoporosis is characterised by reduced bone mass and disordered bone microstructure, which collectively result in increased fracture risk. Data from the National Health and Nutrition Examination Survey document a prevalence of osteoporosis of 12·6% in adults aged 50 years or older in the (...) (The Lancet Diabetes & Endocrinology 12, 4 (2024))
• 00:30
  [In Focus] Bariatric tourism - Talha Burki Lancet Diab Endocrinol
  Obtaining bariatric surgery in England is not easy. Even getting the initial referral can be a challenge. Francesco Rubino, Chair of Metabolic and Bariatric Surgery at King's College London, London, UK, noted that a lot of a general practitioners (GPs) harbour the misconception that weight (...) (The Lancet Diabetes & Endocrinology 12, 4 (2024))
• 00:30
  [Articles] Duration of fracture prevention after zoledronate treatment in women with osteopenia: observational follow-up of a 6-year randomised controlled trial to 10 years - Ian R Reid, Anne M Horne, Borislav Mihov, Usha Bava, Angela Stewart, Gregory D Gamble Lancet Diab Endocrinol
  The reduced fracture rates following zoledronate in the core trial were substantially maintained for 1·5–3·5 years after the last zoledronate infusion, but not thereafter. (The Lancet Diabetes & Endocrinology 12, 4 (2024))
• 00:30
  [Comment] Long-term trial outcomes of Roux-en-Y gastric bypass and one anastomosis gastric bypass: tipping the scale - Paulina Salminen Lancet Diab Endocrinol
  Obesity is a highly heterogeneous and chronic progressive multifactorial disease that causes multiple comorbidities and early mortality. Metabolic bariatric surgery is the most effective treatment for severe obesity, resulting in substantial sustained weight reduction with improvement in (...) (The Lancet Diabetes & Endocrinology 12, 4 (2024))
• 00:30
  [Articles] Efficacy and safety of one anastomosis gastric bypass versus Roux-en-Y gastric bypass at 5 years (YOMEGA): a prospective, open-label, non-inferiority, randomised extension study - Maud Robert, Tigran Poghosyan, Delphine Maucort-Boulch, Alexandre Filippello, Robert Caiazzo, Adrien Sterkers, Lita Khamphommala, Fabian Reche, Vincent Malherbe, Adriana Torcivia, Toufic Saber, Dominique Delaunay, Carole Langlois-Jacques, Augustin Suffisseau, Sylvie Bin, Emmanuel Disse, François Pattou Lancet Diab Endocrinol
  OAGB was not inferior to RYGB regarding percentage excess BMI loss at 5 years with similar metabolic outcomes. The high rate of clinical gastro-oesophageal reflux disease after OAGB raises questions about its long-term consequences, which need to be further investigated. (The Lancet Diabetes & Endocrinology 12, 4 (2024))

2 mars

Lancet Diab Endocrinol https://www.thelancet.com/journals/landia/home

• 00:30
  [Comment] Reversibility of congenital hypogonadotropic hypogonadism: lessons from a rare disease - Bradley D Anawalt Lancet Diab Endocrinol
  Congenital hypogonadotropic hypogonadism (CHH) is caused by abnormal gonadotropin secretion or action. Although rare, CHH is approximately twice as common in men than in women.1,2 Around 50% of patients with CHH have anosmia (Kallmann syndrome).1,2 CHH is generally first suspected by the (...) (The Lancet Diabetes & Endocrinology 12, 4 (2024))
• 00:30
  [Articles] Classes and predictors of reversal in male patients with congenital hypogonadotropic hypogonadism: a cross-sectional study of six international referral centres - Andrew A Dwyer, Isabella R McDonald, Biagio Cangiano, Luca Giovanelli, Luigi Maione, Leticia F G Silveira, Taneli Raivio, Ana Claudia Latronico, Jacques Young, Richard Quinton, Marco Bonomi, Luca Persani, Stephanie B Seminara, Christopher S Lee Lancet Diab Endocrinol
  Applying LCMM to a large cohort of male patients with CHH reversal uncovered two distinct classes of reversal. Genetic investigation combined with careful clinical phenotyping could help surveillance of reversal after withdrawing treatment, representing the first tailored management approach (...) (The Lancet Diabetes & Endocrinology 12, 4 (2024))

1er mars

Lancet Diab Endocrinol https://www.thelancet.com/journals/landia/home

• 00:00
  [Comment] Living between two worlds: lessons for community involvement - Ashley H Ng, Matthew Quigley, Tim Benson, Lauren Cusack, Rachel Hicks, Ben Nash, Meaghan Read, Renza Scibilia, Cheryl Steele, Leon Tribe, Elizabeth Holmes-Truscott Lancet Diab Endocrinol
  Genuine consumer and community involvement offers multiple benefits to people with diabetes, health-care professionals, health services, researchers, and diabetes community organisations.1,2 Co-designed solutions, led by the community, facilitate interventions that better meet the needs of the (...) (The Lancet Diabetes & Endocrinology 12, 3 (2024))
• 00:00
  [Comment] Thank you to The Lancet Diabetes & Endocrinology's statistical and peer reviewers in 2023 - The Lancet Diabetes & Endocrinology Editors Lancet Diab Endocrinol
  Emma Ahlqvist (The Lancet Diabetes & Endocrinology 12, 3 (2024))
• 00:00
  [Correspondence] Milestone achievement for global access to blood glucose meters and test strips - Emma Klatman, Beatrice Vetter, Cathy Haldane, Graham Ogle Lancet Diab Endocrinol
  In October, 2023, WHO's Essential Diagnostics List (EDL) recognised the vital role of blood glucose meters and test strips in the self-monitoring of blood glucose in home settings for people living with insulin-dependent diabetes. Life for a Child and FIND had submitted an application to the (...) (The Lancet Diabetes & Endocrinology 12, 3 (2024))

29 février

Lancet Diab Endocrinol https://www.thelancet.com/journals/landia/home

• 00:30
  [Comment] Type 2 diabetes remission: weight maintenance in the spotlight - Shahrad Taheri Lancet Diab Endocrinol
  Type 2 diabetes, linked to insulin resistance and ?-cell dysfunction due to excess fat deposition in the liver and pancreas, poses a major global health challenge. Current type 2 diabetes management prioritises glucose control, overlooking the potential for disease remission. Spontaneous type (...) (The Lancet Diabetes & Endocrinology 12, 4 (2024))

27 février

Lancet Diab Endocrinol https://www.thelancet.com/journals/landia/home

• 00:30
  [Comment] CONCEPTT to care: the science of implementation in diabetes care - Eleanor M Scott, Helen R Murphy, Karen Kennedy, Partha Kar Lancet Diab Endocrinol
  One of the frustrations one sees in diabetes care, in any sphere, is the patchy implementation of science. Science that has been carefully crafted, designed, been through trials—yet somehow fails to impact the lives of those who it is supposed to benefit. There are multiple reasons for this, (...) (The Lancet Diabetes & Endocrinology 12, 4 (2024))

26 février

Lancet Diab Endocrinol https://www.thelancet.com/journals/landia/home

• 10:41
  [Articles] 5-year follow-up of the randomised Diabetes Remission Clinical Trial (DiRECT) of continued support for weight loss maintenance in the UK: an extension study - Michael EJ Lean, Wilma S Leslie, Alison C Barnes, Naomi Brosnahan, George Thom, Louise McCombie, Tara Kelly, Keaton Irvine, Carl Peters, Sviatlana Zhyzhneuskaya, Kieren G Hollingsworth, Ashley J Adamson, Falko F Sniehotta, John C Mathers, Yvonne McIlvenna, Paul Welsh, Alex McConnachie, Alasdair McIntosh, Naveed Sattar, Roy Taylor Lancet Diab Endocrinol
  The extended DiRECT intervention was associated with greater aggregated and absolute weight loss, and suggested improved health status over 5 years. (The Lancet Diabetes & Endocrinology 12, 4 (2024))

17 février

Lancet Diab Endocrinol https://www.thelancet.com/journals/landia/home

• 00:30
  [Comment] Denosumab in the treatment of osteoporosis associated with chronic kidney disease - Adrian Covic, Mugurel Apetrii Lancet Diab Endocrinol
  Osteoporosis is a substantial health concern worldwide, particularly among individuals with advanced chronic kidney disease (CKD). In this population, bone fragility is a prevalent complication attributable to disruptions in mineral and hormonal equilibria, leading to a non-vertebral-fracture (...) (The Lancet Diabetes & Endocrinology 12, 4 (2024))

10 février

Lancet Diab Endocrinol https://www.thelancet.com/journals/landia/home

• 00:30
  [Editorial] Women in science: inspiring future generations - The Lancet Diabetes & Endocrinology Lancet Diab Endocrinol
  Feb 11 marks International Day of Women and Girls in Science, an annual observance established by the UN General Assembly on Dec 22, 2015, to promote gender equality in the fields of science, technology, engineering, and mathematics (STEM). This year, the theme is Women and Girls in Science (...) (The Lancet Diabetes & Endocrinology 12, 3 (2024))

6 février

Lancet Diab Endocrinol https://www.thelancet.com/journals/landia/home

• 00:30
  [Comment] GLP-1 analogue therapy for obesity in people from Asia - Bernard Khoo, Tricia M-M Tan Lancet Diab Endocrinol
  Obesity and overweight has become prevalent in Asian populations. It is estimated that 1 billion people across Asia have a BMI higher than 25 kg/m2,1 and that one in three people in China has obesity. Economic development, increased accessibility of foods, changes in dietary pattern, and (...) (The Lancet Diabetes & Endocrinology 12, 3 (2024))
• 00:30
  [Comment] Glucagon—a new player in weight management therapeutics? - Stephen C Bain, David M Williams Lancet Diab Endocrinol
  GLP-1 receptor agonists were first launched as glucose-lowering therapies for people with type 2 diabetes in 2005. GLP-1 receptor agonists are peptides, initially available as twice-daily injections but later formulated for once-weekly subcutaneous administration and more recently once-daily (...) (The Lancet Diabetes & Endocrinology 12, 3 (2024))
• 00:30
  [Articles] Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial - Carel W le Roux, Oren Steen, Kathryn J Lucas, Elena Startseva, Anna Unseld, Anita M Hennige Lancet Diab Endocrinol
  All tested survodutide doses were tolerated, and dose-dependently reduced bodyweight. (The Lancet Diabetes & Endocrinology 12, 3 (2024))
• 00:30
  [Articles] Efficacy and safety of once weekly semaglutide 2·4 mg for weight management in a predominantly east Asian population with overweight or obesity (STEP 7): a double-blind, multicentre, randomised controlled trial - Yiming Mu, Xiaolei Bao, Freddy G Eliaschewitz, Morten Rix Hansen, Bom Taeck Kim, Anna Koroleva, Ronald C W Ma, Tao Yang, Ning Zu, Ming Liu, STEP 7 Study Group Lancet Diab Endocrinol
  The results of this study support the use of semaglutide 2·4 mg for weight management in people of east Asian ethnicity with overweight or obesity and with or without type 2 diabetes. (The Lancet Diabetes & Endocrinology 12, 3 (2024))

2 février

Lancet Diab Endocrinol https://www.thelancet.com/journals/landia/home

• 00:30
  [Articles] PCSK9 inhibition with orally administered NNC0385-0434 in hypercholesterolaemia: a randomised, double-blind, placebo-controlled and active-controlled phase 2 trial - Michael J Koren, Olivier Descamps, Yoshiki Hata, Ellen Margo Hengeveld, G Kees Hovingh, Ignatios Ikonomidis, Maria D Radu Juul Jensen, Irene Hedelund Langbakke, Fabrice M A C Martens, Anette Luther Søndergaard, Adam Witkowski, Wolfgang Koenig Lancet Diab Endocrinol
  This study showed excellent 12-week LDL cholesterol lowering efficacy and good patient tolerance of an oral PCSK9 inhibitor, NNC0835-0434, similar to an injectable drug. However, the sponsor chose to discontinue further development of NNC0835-0434 due to portfolio considerations. (The Lancet Diabetes & Endocrinology 12, 3 (2024))
• 00:30
  [Review] Air pollution exposure and cardiometabolic risk - Sanjay Rajagopalan, Robert D Brook, Pedro R V O Salerno, Brendan Bourges-Sevenier, Philip Landrigan, Mark J Nieuwenhuijsen, Thomas Munzel, Salil V Deo, Sadeer Al-Kindi Lancet Diab Endocrinol
  The Global Burden of Disease assessment estimates that 20% of global type 2 diabetes cases are related to chronic exposure to particulate matter (PM) with a diameter of 2·5 ?m or less (PM2·5). With 99% of the global population residing in areas where air pollution levels are above current WHO (...) (The Lancet Diabetes & Endocrinology 12, 3 (2024))
• 00:30
  [Comment] An anti-PCSK9 pill a day to keep cholesterol away: next steps? - Gerald F Watts Lancet Diab Endocrinol
  Elevated plasma LDL cholesterol is a major cause of atherosclerotic cardiovascular disease. Accordingly, all clinical practice guidelines advise decreasing LDL cholesterol to very low concentrations ( (The Lancet Diabetes & Endocrinology 12, 3 (2024))

1er février

Lancet Diab Endocrinol https://www.thelancet.com/journals/landia/home

• 00:00
  [Review] The impact of the COVID-19 pandemic and associated disruptions in health-care provision on clinical outcomes in people with diabetes: a systematic review - Jamie Hartmann-Boyce, Patrick Highton, Karen Rees, Igho Onakpoya, Jana Suklan, Ffion Curtis, Lauren O'Mahoney, Elizabeth Morris, Laura Kudlek, Jessica Morgan, Rosie Lynch, Sanjana Marpadga, Samuel Seidu, Kamlesh Khunti Lancet Diab Endocrinol
  The COVID-19 pandemic triggered disruptions to health care and lifestyles that could conceivably impact diabetes management. We set out to identify the impact of disruptions caused by COVID-19 on clinical outcomes in people with diabetes. We performed a systematic review of the available (...) (The Lancet Diabetes & Endocrinology 12, 2 (2024))
• 00:00
  [Articles] Association of glycaemic index and glycaemic load with type 2 diabetes, cardiovascular disease, cancer, and all-cause mortality: a meta-analysis of mega cohorts of more than 100 000 participants - David J A Jenkins, Walter C Willett, Salim Yusuf, Frank B Hu, Andrea J Glenn, Simin Liu, Andrew Mente, Victoria Miller, Shrikant I Bangdiwala, Hertzel C Gerstein, Sabina Sieri, Pietro Ferrari, Alpa V Patel, Marjorie L McCullough, Loïc Le Marchand, Neal D Freedman, Erikka Loftfield, Rashmi Sinha, Xiao-Ou Shu, Mathilde Touvier, Norie Sawada, Shoichiro Tsugane, Piet A van den Brandt, Kerem Shuval, Tauseef Ahmad Khan, Melanie Paquette, Sandhya Sahye-Pudaruth, Darshna Patel, Teenie Fei Yi Siu, Korbua Srichaikul, Cyril W C Kendall, John L Sievenpiper, Clinical Nutrition & Risk Factor (…) Lancet Diab Endocrinol
  Dietary recommendations to reduce GI and GL could have effects on health outcomes that are similar to outcomes of recommendations to increase intake of fibre and whole grain. (The Lancet Diabetes & Endocrinology 12, 2 (2024))
• 00:00
  [Corrections] Correction to Lancet Diabetes Endocrinol 2023; 11: 42–57 Lancet Diab Endocrinol
  Battelino T, Alexander CM, Amiel SA, et al. Continuous glucose monitoring and metrics for clinical trials: an international consensus statement. Lancet Diabetes Endocrinol 2023; 11: 42–57—In this Review, some values in table 3 should have read 3·9. This correction has been made to the online (...) (The Lancet Diabetes & Endocrinology 12, 2 (2024))
• 00:00
  [In Focus] Rafik Jacob: Caring for the most vulnerable - Talha Burki Lancet Diab Endocrinol
  Growing up in Egypt, back in the early 1970s, Rafik Jacob was struck by the challenges faced by families who had children with intellectual and developmental disabilities. “There were not a lot of resources around. Parents had to figure everything out for themselves. The whole family was (...) (The Lancet Diabetes & Endocrinology 12, 2 (2024))
• 00:00
  [Comment] Anti-obesity drugs, eating disorders, and thinness among Japanese young women - Shotaro Kinoshita, Taishiro Kishimoto Lancet Diab Endocrinol
  Recently, GLP-1 receptor agonists, which were originally developed for the treatment of diabetes, have attracted much attention because of their weight loss effects in people with obesity. In Japan, GLP-1 receptor agonists were approved for the treatment of diabetes in January, 2010, and in (...) (The Lancet Diabetes & Endocrinology 12, 2 (2024))
• 00:00
  [Comment] Association of glycaemic index and glycaemic load with type 2 diabetes and related conditions in prospective studies - Gabriele Riccardi, Olga Vaccaro Lancet Diab Endocrinol
  There is debate over the nature of the carbohydrate-containing foods that should be recommended to reduce the risk of type 2 diabetes and related conditions. In particular, it is not well established whether glycaemic index (GI) is a relevant dietary factor for the prevention of chronic (...) (The Lancet Diabetes & Endocrinology 12, 2 (2024))
• 00:00
  [Editorial] The price of health - The Lancet Diabetes & Endocrinology Lancet Diab Endocrinol
  The burden of non-communicable diseases (NCDs) cannot be understated. Chronic diseases, including cardiovascular diseases, cancers, chronic respiratory diseases, and diabetes, are responsible for 41 million deaths, almost three-quarters of all deaths globally. Even more alarming is that 17 (...) (The Lancet Diabetes & Endocrinology 12, 2 (2024))

30 janvier

Lancet Diab Endocrinol https://www.thelancet.com/journals/landia/home

• 00:30
  [Corrections] Correction to Lancet Diabetes Endocrinol 2024; 12: 39–50 Lancet Diab Endocrinol
  The EMPA-KIDNEY Collaborative Group. Effects of empagliflozin on progression of chronic kidney disease: a prespecified secondary analysis from the EMPA-KIDNEY trial. Lancet Diabetes Endocrinol 2024; 12: 39–50—In table 1 of this Article, the mean values in the “HbA1c, %” row have been (...) (The Lancet Diabetes & Endocrinology 12, 3 (2024))
• 00:30
  [Personal View] A proposed clinical classification for pituitary neoplasms to guide therapy and prognosis - Ken K Y Ho, Maria Fleseriu, John Wass, Laurence Katznelson, Gerald Raverot, Andrew S Little, Justo P Castaño, Martin Reincke, M Beatriz Lopes, Ursula B Kaiser, Philippe Chanson, Mônica Gadelha, Shlomo Melmed Lancet Diab Endocrinol
  No comprehensive classification system that guides prognosis and therapy of pituitary adenomas exists. The 2022 WHO histopathology-based classification system can only be applied to lesions that are resected, which represent few clinically significant pituitary adenomas. Many factors (...) (The Lancet Diabetes & Endocrinology 12, 3 (2024))
• 00:30
  [In Focus] TB Joshua and his megachurch: fake medical miracles and abuse in Nigeria - Talha Burki Lancet Diab Endocrinol
  On Jan 8, 2024, the BBC released a three-part television Documentary Series and a nine-part radio show on the powerful preacher TB Joshua and the megachurch that he founded. The programmes were the culmination of a lengthy investigation by the BBC and openDemocracy into the Synagogue Church of (...) (The Lancet Diabetes & Endocrinology 12, 3 (2024))

6 janvier

Lancet Diab Endocrinol https://www.thelancet.com/journals/landia/home

• 00:30
  [In Focus] The fight to put food on the table: from past to present - Talha Burki Lancet Diab Endocrinol
  Roughly halfway through Stuffed: A History of Good Food and Hard Times in Britain, Pen Vogler likens supermarkets to the protagonist in Goethe's The Sorcerer's Apprentice. “The novice knows how to cast a spell to get his broom to bring water—but not the magic to end it”, writes Vogler. “His (...) (The Lancet Diabetes & Endocrinology 12, 2 (2024))

5 janvier

Lancet Diab Endocrinol https://www.thelancet.com/journals/landia/home

• 00:30
  [In Focus] Better testing and labelling of drugs for people with obesity - Talha Burki Lancet Diab Endocrinol
  On Nov 28, 2023, several obesity advocacy organisations issued a joint statement calling on the US Food and Drug Administration (FDA) to stipulate that people with obesity must be included in drug trials. They also asked the FDA to mandate that any obesity-related differences in the (...) (The Lancet Diabetes & Endocrinology 12, 2 (2024))

4 janvier

Lancet Diab Endocrinol https://www.thelancet.com/journals/landia/home

• 00:30
  [Comment] The role of medical students in humanitarian responses to armed conflict - Ji Won Susie Yoo, Rahul D Barmanray Lancet Diab Endocrinol
  The Russia–Ukraine and Israel–Palestine armed conflicts have been widely covered by the media in 2023. However, on a global scale, humanity is no stranger to violence with many countries currently experiencing armed conflict, terrorism, political unrest, or ethnic violence.1 There is great (...) (The Lancet Diabetes & Endocrinology 12, 2 (2024))

1er janvier

Lancet Diab Endocrinol https://www.thelancet.com/journals/landia/home

• 00:00
  [Review] Bringing an end to diabetes stigma and discrimination: an international consensus statement on evidence and recommendations - Jane Speight, Elizabeth Holmes-Truscott, Matthew Garza, Renza Scibilia, Sabina Wagner, Asuka Kato, Victor Pedrero, Sonya Deschênes, Susan J Guzman, Kevin L Joiner, Shengxin Liu, Ingrid Willaing, Katie M Babbott, Bryan Cleal, Jane K Dickinson, Jennifer A Halliday, Eimear C Morrissey, Giesje Nefs, Shane O'Donnell, Anna Serlachius, Per Winterdijk, Hamzah Alzubaidi, Bustanul Arifin, Liz Cambron-Kopco, Corinna Santa Ana, Emma Davidsen, Mary de Groot, Maartje de Wit, Phyllisa Deroze, Stephanie Haack, Richard I G Holt, Walther Jensen, Kamlesh Khunti, Karoline Kragelund Nielsen, Tejal Lathia, (…) Lancet Diab Endocrinol
  People with diabetes often encounter stigma (ie, negative social judgments, stereotypes, prejudice), which can adversely affect emotional, mental, and physical health; self-care, access to optimal health care; and social and professional opportunities. To accelerate an end to diabetes stigma (...) (The Lancet Diabetes & Endocrinology 12, 1 (2024))
• 00:00
  [Editorial] From research to policy: still a long way to go - The Lancet Diabetes & Endocrinology Lancet Diab Endocrinol
  As 2023 draws to a close, it is time to reflect upon and celebrate the year's most impactful research findings in diabetes and endocrinology. However, this last Editorial of the year will not highlight those findings—as rewarding as that might have been for both editors and readers. Instead, (...) (The Lancet Diabetes & Endocrinology 12, 1 (2024))

22 décembre

Lancet Diab Endocrinol https://www.thelancet.com/journals/landia/home

• 00:30
  [Articles] Daily low-dose aspirin and incident type 2 diabetes in community-dwelling healthy older adults: a post-hoc analysis of efficacy and safety in the ASPREE randomised placebo-controlled trial - Sophia Zoungas, Zhen Zhou, Alice J Owen, Andrea J Curtis, Sara E Espinoza, Michael E Ernst, Robyn L Woods, Suzanne G Orchard, John J McNeil, Anne M Murray, Mark R Nelson, Christopher M Reid, Joanne Ryan, Rory Wolfe Lancet Diab Endocrinol
  Aspirin treatment reduced the incidence of type 2 diabetes and slowed the increase in FPG concentration but increased major bleeding among community-dwelling older adults. Given the increasing prevalence of type 2 diabetes among older adults, the potential for anti-inflammatory agents such as (...) (The Lancet Diabetes & Endocrinology 12, 2 (2024))
• 00:30
  [Comment] Advancing precision medicine in type 2 diabetes - Jose C Florez Lancet Diab Endocrinol
  An emerging consensus in the diabetes field postulates that the traditional subclassification of diabetes into type 1 diabetes, type 2 diabetes, gestational diabetes, monogenic or syndromic diabetes, or diabetes secondary to underlying pancreatic disease is outdated. Global efforts such as the (...) (The Lancet Diabetes & Endocrinology 12, 2 (2024))
• 00:30
  [Articles] Analysis of type 2 diabetes heterogeneity with a tree-like representation: insights from the prospective German Diabetes Study and the LURIC cohort - Martin Schön, Katsiaryna Prystupa, Tim Mori, Oana P Zaharia, Kálmán Bódis, Maria Bombrich, Clara Möser, Iryna Yurchenko, Yuliya Kupriyanova, Klaus Strassburger, Pavel Bobrov, Anand T N Nair, Gidon J Bönhof, Alexander Strom, Graciela E Delgado, Sema Kaya, Rainer Guthoff, Norbert Stefan, Andreas L Birkenfeld, Hans Hauner, Jochen Seissler, Andreas Pfeiffer, Matthias Blüher, Stefan Bornstein, Julia Szendroedi, Svenja Meyhöfer, Sandra Trenkamp, Volker Burkart, Vera B Schrauwen-Hinderling, Marcus E Kleber, Alexander Niessner, Christian Herder, Oliver Kuss, Winfried März, Ewan R Pearson, Michael (…) Lancet Diab Endocrinol
  These data define the pathophysiological underpinnings of the tree structure, which has the potential to stratify diabetes-related complications on the basis of routinely available variables and thereby expand the toolbox of precision diabetes diagnosis. (The Lancet Diabetes & Endocrinology 12, 2 (2024))
• 00:30
  [Comment] Aspirin and diabetes prevention among healthy older adults—practice-changing or hypothesis-generating? - John W Ostrominski, Vanita R Aroda Lancet Diab Endocrinol
  The global prevalence of diabetes—the vast majority of which is type 2 diabetes—increases steeply with age, affecting approximately one in four adults aged 75–79 years.1 As such, diabetes is an exceedingly common condition among older adults. Although younger populations generally experience (...) (The Lancet Diabetes & Endocrinology 12, 2 (2024))

19 décembre

Lancet Diab Endocrinol https://www.thelancet.com/journals/landia/home

• 00:30
  [Comment] Enhancing global access to diabetes medicines: policy lessons from the HIV response - Felix Teufel, Caroline A Bulstra, Justine I Davies, Mohammed K Ali Lancet Diab Endocrinol
  One of the biggest global health success stories is the response to the HIV pandemic over the past three decades. Scientists, clinicians, activists, policy makers, and pharmaceutical companies turned a deadly disease into a treatable disease by ensuring near-universal access to antiretroviral (...) (The Lancet Diabetes & Endocrinology 12, 2 (2024))

12 décembre

Lancet Diab Endocrinol https://www.thelancet.com/journals/landia/home

• 00:30
  [Corrections] Correction to Lancet Diabetes Endocrinol 2023; 11: 915–25 Lancet Diab Endocrinol
  Taylor PN, Collins KS, Lam A, et al. C-peptide and metabolic outcomes in trials of disease modifying therapy in new-onset type 1 diabetes: an individual participant meta-analysis. Lancet Diabetes Endocrinol 2023; 11: 915–25—In this Article, the x axis for figures 2A–F should have been labelled (...) (The Lancet Diabetes & Endocrinology 12, 2 (2024))

5 décembre

Lancet Diab Endocrinol https://www.thelancet.com/journals/landia/home

• 00:30
  [Articles] Effects of empagliflozin on progression of chronic kidney disease: a prespecified secondary analysis from the empa-kidney trial - The EMPA-KIDNEY Collaborative Group Lancet Diab Endocrinol
  Empagliflozin slowed the rate of progression of chronic kidney disease among all types of participant in the EMPA-KIDNEY trial, including those with little albuminuria. Albuminuria alone should not be used to determine whether to treat with an SGLT2 inhibitor. (The Lancet Diabetes & Endocrinology 12, 1 (2024))
• 00:30
  [Articles] Efficacy and safety of bempedoic acid among patients with and without diabetes: prespecified analysis of the CLEAR Outcomes randomised trial - Kausik K Ray, Stephen J Nicholls, Na Li, Michael J Louie, Danielle Brennan, A Michael Lincoff, Steven E Nissen, CLEAR OUTCOMES Committees and Investigators Lancet Diab Endocrinol
  Among patients with diabetes, bempedoic acid reduces LDL cholesterol and high-sensitivity C-reactive protein and risk of cardiovascular events. Patients without diabetes had no increase in new-onset diabetes or worsening HbA1c with bempedoic acid. The efficacy and cardiometabolic safety (...) (The Lancet Diabetes & Endocrinology 12, 1 (2024))
• 00:30
  [Articles] Impact of primary kidney disease on the effects of empagliflozin in patients with chronic kidney disease: secondary analyses of the EMPA-KIDNEY trial - The EMPA-KIDNEY Collaborative Group Lancet Diab Endocrinol
  In a broad range of patients with chronic kidney disease at risk of progression, including a wide range of non-diabetic causes of chronic kidney disease, empagliflozin reduced risk of kidney disease progression. Relative effect sizes were broadly similar irrespective of the cause of primary (...) (The Lancet Diabetes & Endocrinology 12, 1 (2024))
• 00:30
  [Comment] Empagliflozin in chronic kidney disease: nephroprotection is independent of albuminuria, primary kidney disease, and baseline eGFR - Carmine Zoccali, Francesca Mallamaci Lancet Diab Endocrinol
  Chronic kidney disease, a disease attributable to diabetes in 30–40% of patients, is a major health burden worldwide because it underlies an excess risk for kidney failure cardiovascular disease events.1 Large, randomised placebo-controlled trials have shown that renin–angiotensin system (RAS) (...) (The Lancet Diabetes & Endocrinology 12, 1 (2024))
• 00:30
  [Comment] New clarity for managing statin intolerance in diabetes - Robert A Hegele Lancet Diab Endocrinol
  In clinical practice guidelines, diabetes is a statin-indicated condition.1 Reducing LDL cholesterol by 1 mmol/L with statin therapy reduces overall mortality by 9% and cardiovascular mortality by 13% in patients with diabetes,2 reinforcing this treatment's foundational role. Non-statin agents (...) (The Lancet Diabetes & Endocrinology 12, 1 (2024))

2 décembre

Lancet Diab Endocrinol https://www.thelancet.com/journals/landia/home

• 00:30
  [Articles] Vitamin D supplements for fracture prevention in schoolchildren in Mongolia: analysis of secondary outcomes from a multicentre, double-blind, randomised, placebo-controlled trial - Davaasambuu Ganmaa, Polyna Khudyakov, Uyanga Buyanjargal, Enkhtsetseg Tserenkhuu, Sumiya Erdenenbaatar, Chuluun-Erdene Achtai, Narankhuu Yansanjav, Baigal Delgererekh, Munkhzaya Ankhbat, Enkhjargal Tsendjav, Batbayar Ochirbat, Badamtsetseg Jargalsaikhan, Davaasambuu Enkhmaa, Adrian R Martineau Lancet Diab Endocrinol
  Oral vitamin D supplementation at a dose of 14 000 IU/week for 3 years was safe, but did not influence fracture risk in schoolchildren living in Mongolia who had a high baseline prevalence of vitamin D deficiency. (The Lancet Diabetes & Endocrinology 12, 1 (2024))
• 00:30
  [Comment] Mendelian randomisation at 20 years: how can it avoid hubris, while achieving more? - George Davey Smith, Shah Ebrahim Lancet Diab Endocrinol
  Mendelian randomisation, the initial extended formulation of which appeared 20 years ago,1 uses germline genetic variation to strengthen causal inference regarding modifiable risk factors for disease. In the original formulation, a genetic variant of known function, often a single-nucleotide (...) (The Lancet Diabetes & Endocrinology 12, 1 (2024))
• 00:30
  [Comment] Screening type 1 diabetes and celiac disease by law - Emanuele Bosi, Carlo Catassi Lancet Diab Endocrinol
  On Sept 17, 2023, the Italian Parliament approved with unanimous vote a law (Italian Republic Law 130/2023) introducing a nationwide screening for type 1 diabetes and coeliac disease in the general population aged 1–17 years as part of the public health program aimed at reducing the effects of (...) (The Lancet Diabetes & Endocrinology 12, 1 (2024))
• 00:30
  [Comment] The role of vitamin D in paediatric bone health - John M Pettifor, Kebashni Thandrayen Lancet Diab Endocrinol
  Vitamin D is important in maintaining children's bone health. Certainly, there is good evidence that vitamin D deficiency and low dietary calcium intake are major contributors in the pathogenesis of nutritional rickets; however, it remains unclear what the role of vitamin D sufficiency is in (...) (The Lancet Diabetes & Endocrinology 12, 1 (2024))
• 00:30
  [Comment] Retraction and republication—Estimating dose-response relationships for vitamin D with coronary heart disease, stroke, and all-cause mortality: observational and Mendelian randomisation analyses - The Editors of The Lancet Diabetes & Endocrinology Lancet Diab Endocrinol
  On Oct 27, 2021, The Lancet Diabetes & Endocrinology published online the Article, “Estimating dose-response relationships for vitamin D with coronary heart disease, stroke, and all-cause mortality: observational and Mendelian randomisation analyses”, and the Article was published in print (...) (The Lancet Diabetes & Endocrinology 12, 1 (2024))
• 00:30
  [Articles] Estimating dose-response relationships for vitamin D with coronary heart disease, stroke, and all-cause mortality: observational and Mendelian randomisation analyses - Emerging Risk Factors Collaboration/EPIC-CVD/Vitamin D Studies Collaboration Lancet Diab Endocrinol
  Stratified Mendelian randomisation analyses suggest a lack of causal relationship for 25(OH)D concentrations with both cardiovascular and mortality outcomes for individuals at all levels of 25(OH)D. Our findings suggest that substantial reductions in mortality and cardiovascular morbidity due (...) (The Lancet Diabetes & Endocrinology 12, 1 (2024))

1er décembre

Lancet Diab Endocrinol https://www.thelancet.com/journals/landia/home

• 00:00
  [Correspondence] Metabolic non-communicable diseases in India: time to act – Authors' reply - Ranjit Mohan Anjana, Ranjit Unnikrishnan, Rajendra Pradeepa, Mohan Deepa, Viswanathan Mohan Lancet Diab Endocrinol
  We thank Shikha Nag and colleagues for their interest in our Article reporting on metabolic non-communicable diseases (NCDs) in India.1 While we appreciate their concern that the ICMR-INDIAB study does not encompass the entirety of India's population (particularly the underprivileged (...) (The Lancet Diabetes & Endocrinology 11, 12 (2023))
• 00:00
  [In Focus] Chronicling insulin from discovery to crisis - Talha Burki Lancet Diab Endocrinol
  It took a while for Stuart Bradwel to get accustomed to the idea that he had type 1 diabetes. “Insulin therapy involved a great deal more than just doing injections”, notes Bradwel, in the preface to Insulin: A Hundred Year History. “Much more challenging was what it did to my sense of self”. (...) (The Lancet Diabetes & Endocrinology 11, 12 (2023))
• 00:00
  [Correspondence] Metabolic non-communicable diseases in India: time to act - Shifa Habeeb, Kavumpurathu Raman Thankappan Lancet Diab Endocrinol
  The Article by Ranjit Mohan Anjana and colleagues1 non-communicable disease (NCDs) burden in India, which is much higher than previous reports. For example, in this Article, the number of people with diabetes is estimated to be 101 million, 36% higher than the 74·2 million reported by the (...) (The Lancet Diabetes & Endocrinology 11, 12 (2023))
• 00:00
  [Correspondence] Comparing the effectiveness of glucose-lowering agents: real-world data to emulate a four-arm target trial – Authors' reply - Yan Xie, Ziyad Al-Aly Lancet Diab Endocrinol
  We thank Ali Ahmed and colleagues for their interest in our study of the comparative effectiveness of four antihyperglycaemics on the risk of major adverse cardiovascular events (MACE).1 However, they do not seem to appreciate the merit of the target trial emulation approach in general and (...) (The Lancet Diabetes & Endocrinology 11, 12 (2023))
• 00:00
  [Correspondence] Metabolic non-communicable diseases in India: time to act - Shikha Nag, Suyesh Shrivastava, Tapas Chakma Lancet Diab Endocrinol
  Amidst the global COVID-19 pandemic, health-care sectors have primarily focused on combating infectious diseases, given their immediate impact on morbidity and mortality. However, it is essential to acknowledge that there has also been a tremendous increase in the prevalence of metabolic (...) (The Lancet Diabetes & Endocrinology 11, 12 (2023))
• 00:00
  [Correspondence] Comparing the effectiveness of glucose-lowering agents: real-world data to emulate a four-arm target trial - Antonio Ceriello, Francesco Prattichizzo, Cesare Celeste Berra, Augusto Enrique Caballero Lancet Diab Endocrinol
  SGLT2 inhibitors have a protective effect for the cardiovascular system and for the kidney.1 It is recommended to add these drugs in the treatment of type 2 diabetes when cardiovascular disease or kidney disease is prevalent. However, a matter of debate is the possible usefulness of using this (...) (The Lancet Diabetes & Endocrinology 11, 12 (2023))
• 00:00
  [Correspondence] Comparing the effectiveness of glucose-lowering agents: real-world data to emulate a four-arm target trial - Mirac Vural Keskinler, Ozge Telci Caklili, Aytekin Oguz Lancet Diab Endocrinol
  We read the study by Yan Xie and colleagues1 with great interest. The study filled a gap in the evidence for the cardiovascular effects of diabetes medications by using an original method of emulation of a randomised pragmatic clinical trial. The findings of the study showed that SGLT2 (...) (The Lancet Diabetes & Endocrinology 11, 12 (2023))
• 00:00
  [Correspondence] Comparing the effectiveness of glucose-lowering agents: real-world data to emulate a four-arm target trial - Ali Ahmed, Stefan D Anker, Javed Butler, George L Bakris, Deepak L Bhatt, Gregg C Fonarow, Milton Packer Lancet Diab Endocrinol
  We read the study by Yan Xie and colleagues1 with interest. Findings of this observational retrospective cohort study suggest that both SGLT2 inhibitors and GLP-1 receptor agonists are associated with a lower risk of major adverse cardiovascular events compared with DPP-4 inhibitors or (...) (The Lancet Diabetes & Endocrinology 11, 12 (2023))
• 00:00
  [Comment] Challenges in implementing nationwide epidemiological studies on metabolic non-communicable diseases in low-income and middle-income countries - Ranjit Mohan Anjana, Nirmal Elangovan, Rajendra Pradeepa, Mohan Deepa, Ranjit Unnikrishnan, Viswanathan Mohan Lancet Diab Endocrinol
  Metabolic non-communicable diseases (NCDs), such as diabetes, hypertension, and cardiovascular disease, are leading causes of morbidity and mortality worldwide. Planning and implementation of preventive and therapeutic measures to stop the global pandemic of metabolic NCDs require accurate (...) (The Lancet Diabetes & Endocrinology 11, 12 (2023))
• 00:00
  [Country Focus] Iodine status in Iran: from deficient to replete - Fereidoun Azizi, Hossein Delshad, Mehdi Hedayati, Parvin Mirmiran Lancet Diab Endocrinol
  Thyroid hormones are pivotal regulators of cellular metabolism, growth, and developmental progression. To function effectively, thyroid hormones depend on having an adequate supply of a critical micronutrient called iodine. When the body does not receive enough iodine to produce the necessary (...) (The Lancet Diabetes & Endocrinology 11, 12 (2023))
• 00:00
  [Corrections] Correction to Lancet Diabetes Endocrinol 2023; 11: 720–30 Lancet Diab Endocrinol
  Terzolo M, Fassnacht M, Perotti P, et al. Adjuvant mitotane versus surveillance in low-grade, localised adrenocortical carcinoma (ADIUVO): an international, multicentre, open-label, randomised, phase 3 trial and observational study. Lancet Diabetes Endocrinol 2023; 11: 720–30—The Summary and (...) (The Lancet Diabetes & Endocrinology 11, 12 (2023))

29 novembre

Lancet Diab Endocrinol https://www.thelancet.com/journals/landia/home

• 00:30
  [Corrections] Correction to Lancet Diabetes Endocrinol 2023; 11: 942–54 Lancet Diab Endocrinol
  Nazari MA, Hasan R, Haigney M, et al. Catecholamine-induced hypertensive crises: current insights and management. Lancet Diabetes Endocrinol 2023; 11: 942–54—In this Review, the last sentence of the last paragraph of the section entitled “Endocrine physiology and pathophysiology” should have (...) (The Lancet Diabetes & Endocrinology 12, 1 (2024))
• 00:30
  [Corrections] Correction to Lancet Diabetes Endocrinol 2023; 11: 905–14 Lancet Diab Endocrinol
  RECOVERY Collaborative Group. Empagliflozin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet Diabetes Endocrinol 2023; 11: 905–14—In the Summary of this Article, the Funding line should have read “UK Research and Innovation (...) (The Lancet Diabetes & Endocrinology 12, 1 (2024))
• 00:30
  [In Focus] South Africa to produce insulin for Africa in 2024 - Munyaradzi Makoni Lancet Diab Endocrinol
  A collaboration between a global leader in diabetes research and innovation (Novo Nordisk) and Africa's largest pharmaceutical manufacturer (Aspen) will result in the production of human insulin in South Africa in 2024 to cater for people with diabetes across the continent. Aspen was (...) (The Lancet Diabetes & Endocrinology 12, 1 (2024))

24 novembre

Lancet Diab Endocrinol https://www.thelancet.com/journals/landia/home

• 00:30
  [Corrections] Correction to Lancet Diabetes Endocrinol 2023; 11: 798–810 Lancet Diab Endocrinol
  Sandforth A, von Schwartzenberg RJ, Arreola EV, al. Mechanisms of weight loss-induced remission in people with prediabetes: a post-hoc analysis of the randomised, controlled, multicentre Prediabetes Lifestyle Intervention Study (PLIS). Lancet Diabetes Endocrinol 2023; 11: 798–810—In this (...) (The Lancet Diabetes & Endocrinology 12, 1 (2024))

18 novembre

Lancet Diab Endocrinol https://www.thelancet.com/journals/landia/home

• 00:30
  [Comment] Is a new discussion about diagnosis of gestational diabetes needed? - Gernot Desoye, Mireille van Poppel Lancet Diab Endocrinol
  Gestational diabetes is a metabolic condition occurring in pregnant women, usually diagnosed between 24 weeks and 28 weeks of gestation. This timing was chosen to strike a balance between optimising sensitivity and allowing the opportunity to manage metabolic dysregulation through lifestyle or (...) (The Lancet Diabetes & Endocrinology 12, 1 (2024))

14 novembre

Lancet Diab Endocrinol https://www.thelancet.com/journals/landia/home

• 00:30
  [Comment] The Lancet Diabetes & Endocrinology Commission on type 1 diabetes: looking back to move forward - David Beran, Marta Koch, Sana Ajmal, Carine de Beaufort, Kaushik Ramaiya, Jessica Hanae Zafra-Tanaka, Mark Atkinson Lancet Diab Endocrinol
  Kofi Annan, former UN Secretary General and Nobel Prize winner, was noted for his many words of wisdom, including: “One has to learn from history. Quite frankly, it is almost impossible to have a sense of vision without a sense of history. If history is learned, then it doesn't have to repeat (...) (The Lancet Diabetes & Endocrinology 12, 1 (2024))
• 00:30
  [Editorial] Diabetes: knowing your risk matters - The Lancet Diabetes & Endocrinology Lancet Diab Endocrinol
  In the third year of the Access to Diabetes Care campaign, World Diabetes Day on Nov 14 highlights the importance of knowing your risk of type 2 diabetes. Under the slogan—Know your risk, Know your response—people are encouraged to use the online type 2 diabetes risk assessment tool developed (...) (The Lancet Diabetes & Endocrinology 11, 12 (2023))

7 novembre

Lancet Diab Endocrinol https://www.thelancet.com/journals/landia/home

• 00:30
  [Review] Catecholamine-induced hypertensive crises: current insights and management - Matthew A Nazari, Rockyb Hasan, Mark Haigney, Alireza Maghsoudi, Jacques W M Lenders, Robert M Carey, Karel Pacak Lancet Diab Endocrinol
  Phaeochromocytomas and paragangliomas (PPGLs) release catecholamines leading to catecholamine-induced hypertensive (CIH) crises, with blood pressure greater than or equal to 180/120 mm Hg. CIH crises can be complicated by tachyarrhythmias, hypotension, or life-threatening target organ damage (...) (The Lancet Diabetes & Endocrinology 11, 12 (2023))

4 novembre

Lancet Diab Endocrinol https://www.thelancet.com/journals/landia/home

• 00:30
  [In Focus] Making adjustments: diabetes and developmental disability - Talha Burki Lancet Diab Endocrinol
  On Sept 15 2023, WHO and UNICEF released a joint report on children with developmental disabilities. It stated that individuals with such disabilities are vulnerable to stigmatisation, prejudice, and social exclusion; they face barriers to accessing care and experience worse health outcomes (...) (The Lancet Diabetes & Endocrinology 11, 12 (2023))
• 00:30
  [Comment] Impact of disease-modifying therapy on ?-cell function and metabolic control in newly diagnosed type 1 diabetes - Mikael Knip Lancet Diab Endocrinol
  Type 1 diabetes is an immune-mediated disease and therefore immunotherapy is a potential modality for halting ?-cell destruction and attenuating C-peptide loss after the diagnosis of clinical diabetes. From the beginning of this century, a series of intervention trials have been done to assess (...) (The Lancet Diabetes & Endocrinology 11, 12 (2023))
• 00:30
  [Articles] C-peptide and metabolic outcomes in trials of disease modifying therapy in new-onset type 1 diabetes: an individual participant meta-analysis - Peter N Taylor, Kimberly S Collins, Anna Lam, Stephen R Karpen, Brianna Greeno, Frank Walker, Alejandro Lozano, Elnaz Atabakhsh, Simi T Ahmed, Marjana Marinac, Esther Latres, Peter A Senior, Mark Rigby, Peter A Gottlieb, Colin M Dayan, Trial Outcome Markers Initiative collaboration Lancet Diab Endocrinol
  Interventions that preserve ?-cell function are effective at improving metabolic outcomes in new-onset type 1 diabetes, confirming their potential as adjuncts to insulin. We have shown that improvements in HbA1c are directly proportional to the degree of C-peptide preservation, quantifying (...) (The Lancet Diabetes & Endocrinology 11, 12 (2023))

3 novembre

Lancet Diab Endocrinol https://www.thelancet.com/journals/landia/home

• 00:30
  [Comment] Tackling the diabetes surge in sub-Saharan Africa through novel youth-centric strategies - Felix P Chilunga, Asanda Mtintsilana, Pearl Aovare, George Msengi, George F Mkoma, Wisdom Nakanga Lancet Diab Endocrinol
  Over the past few decades, diabetes cases in sub-Saharan Africa have shown a substantial increase. According to a recent Global Burden of Disease Study, published in The Lancet, the age-standardised prevalence of diabetes in sub-Saharan Africa rose by 83% between 1990 and 2021, reaching 4248 (...) (The Lancet Diabetes & Endocrinology 11, 12 (2023))

2 novembre

Lancet Diab Endocrinol https://www.thelancet.com/journals/landia/home

• 00:30
  [Comment] Balancing hormonal shifts: exploring the impact of ageing and dietary restriction - Stephen M Twigg, Luigi Fontana Lancet Diab Endocrinol
  In the recent Scientific Statement of the Endocrine Society, Anne R Cappola and colleagues presented a comprehensive overview of ageing's impact on various hormonal axes, highlighting crucial areas for future research.1 As individuals age, all major endocrine systems undergo simultaneous (...) (The Lancet Diabetes & Endocrinology 11, 12 (2023))

1er novembre

Lancet Diab Endocrinol https://www.thelancet.com/journals/landia/home

• 00:00
  [Corrections] Correction to Lancet Diabetes Endocrinol 2023; 11: 785–87 Lancet Diab Endocrinol
  Feig DS. Faster and faster: meeting the challenges of delayed insulin action during pregnancy. Lancet Diabetes Endocrinol 2023; 11: 785–87—In this Comment, the last sentence of the sixth paragraph should have said “a benefit of faster insulin aspart”. This correction has been made as of Oct (...) (The Lancet Diabetes & Endocrinology 11, 11 (2023))
• 00:00
  [In Focus] A letter to my GP - Jessica Catchpole Lancet Diab Endocrinol
  I don't know what you think of me, but I can guess. (The Lancet Diabetes & Endocrinology 11, 11 (2023))
• 00:00
  [Correspondence] Explaining the high rate of progression from prediabetes to type 2 diabetes in China - Natural Chu, Jie He, Kathy H T Leung, Juliana C N Chan, Elaine Chow Lancet Diab Endocrinol
  We read with interest the report on the China Diabetes Prevention Program (CDPP) by Lihui Zhang and colleagues,1 a 2-year open-label randomised controlled trial of metformin plus lifestyle intervention versus lifestyle intervention alone in individuals with impaired glucose regulation in (...) (The Lancet Diabetes & Endocrinology 11, 11 (2023))
• 00:00
  [Correspondence] Explaining the high rate of progression from prediabetes to type 2 diabetes in China – Authors' reply - Lihui Zhang, Qiuhong Gong, Ningling Sun, Linong Ji, Guangwei Li Lancet Diab Endocrinol
  In our recent Article,1 we reported that metformin plus lifestyle intervention was more effective than the lifestyle intervention alone in preventing progression to diabetes in participants with impaired glucose regulation. Our study1 confirmed the high rate of progression from prediabetes to (...) (The Lancet Diabetes & Endocrinology 11, 11 (2023))
• 00:00
  [In Focus] Jonathan Valabhji: from clinical practice to policy making and back - Talha Burki Lancet Diab Endocrinol
  Jonathan Valabhji's parents met in south Wales. His mother's family had been there for generations, but his father's origins lay further afield. “My paternal grandparents were from Gujarat, India. They emigrated to the Seychelles, these beautiful tropical islands in the Indian Ocean”, (...) (The Lancet Diabetes & Endocrinology 11, 11 (2023))
• 00:00
  [Comment] Are we settling for less in nutritional policy? - Neena Prasad, J Jaime Miranda Lancet Diab Endocrinol
  Non-sugar sweeteners such as aspartame have become the subject of substantial media and public interest. This attention follows the publication of a WHO guideline that advises against the use of such sweeteners to control bodyweight or reduce the risk of noncommunicable-diseases (NCDs).1 (...) (The Lancet Diabetes & Endocrinology 11, 11 (2023))

20 octobre

Lancet Diab Endocrinol https://www.thelancet.com/journals/landia/home

• 00:30
  [Comment] Glycaemic fluctuations across the menstrual cycle: possible effect of the brain - Julia Hummel, Stephanie Kullmann, Róbert Wagner, Martin Heni Lancet Diab Endocrinol
  Epidemiological research has identified a lower risk for type 2 diabetes and cardiovascular disease in women who are premenopausal than in men.1,2 However, after menopause, women have a higher risk for these diseases than men do.1,2 The effect of the menstrual cycle on glycaemia is thought to (...) (The Lancet Diabetes & Endocrinology 11, 12 (2023))

19 octobre

Lancet Diab Endocrinol https://www.thelancet.com/journals/landia/home

• 00:30
  [Comment] Empagliflozin in adults hospitalised with COVID-19: a (null) hypothesis for RECOVERY - Monia Garofolo, Giuseppe Penno Lancet Diab Endocrinol
  Soon after the onset of the COVID-19 pandemic, it became apparent that diabetes, obesity, hypertension, underlying cardiovascular, and kidney diseases were associated with an increased mortality rate. Since then, there have been consistent efforts to identify treatments that could lend some (...) (The Lancet Diabetes & Endocrinology 11, 12 (2023))
• 00:30
  [Review] Sex steroids and the female brain across the lifespan: insights into risk of depression and Alzheimer's disease - Claudia Barth, Arielle Crestol, Ann-Marie G de Lange, Liisa A M Galea Lancet Diab Endocrinol
  Despite widespread sex differences in prevalence and presentation of numerous illnesses affecting the human brain, there has been little focus on the effect of endocrine ageing. Most preclinical studies have focused on males only, and clinical studies often analyse data by covarying for sex, (...) (The Lancet Diabetes & Endocrinology 11, 12 (2023))
• 00:30
  [Articles] Empagliflozin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial - RECOVERY Collaborative Group Lancet Diab Endocrinol
  In adults hospitalised with COVID-19, empagliflozin was not associated with reductions in 28-day mortality, duration of hospital stay, or risk of progressing to invasive mechanical ventilation or death so is not indicated for the treatment of such patients unless there is an established (...) (The Lancet Diabetes & Endocrinology 11, 12 (2023))

12 octobre

Lancet Diab Endocrinol https://www.thelancet.com/journals/landia/home

• 00:30
  [Editorial] Precision medicine: improving accuracy, reducing error - The Lancet Diabetes & Endocrinology Lancet Diab Endocrinol
  In 1892 William Osler wrote “It is more important to know what kind of a patient the disease has, than to know what kind of a disease the patient has.” Although health-care practices have traditionally followed a one-size-fits-all method, precision medicine aims for a more tailored approach. (...) (The Lancet Diabetes & Endocrinology 11, 11 (2023))

5 octobre

Lancet Diab Endocrinol https://www.thelancet.com/journals/landia/home

• 00:30
  [Series] The case for precision medicine in the prevention, diagnosis, and treatment of cardiometabolic diseases in low-income and middle-income countries - Shivani Misra, Carlos A Aguilar-Salinas, Tinashe Chikowore, Flemming Konradsen, Ronald C W Ma, Lilian Mbau, Viswanathan Mohan, Robert W Morton, Moffat J Nyirenda, Neo Tapela, Paul W Franks Lancet Diab Endocrinol
  Cardiometabolic diseases are the leading preventable causes of death in most geographies. The causes, clinical presentations, and pathogenesis of cardiometabolic diseases vary greatly worldwide, as do the resources and strategies needed to prevent and treat them. Therefore, there is no single (...) (The Lancet Diabetes & Endocrinology 11, 11 (2023))
• 00:30
  [Articles] Faster-acting insulin aspart versus insulin aspart in the treatment of type 1 or type 2 diabetes during pregnancy and post-delivery (CopenFast): an open-label, single-centre, randomised controlled trial - Sidse K Nørgaard, Julie C Søholm, Elisabeth R Mathiesen, Kirsten Nørgaard, Tine D Clausen, Pernille Holmager, Nicoline C Do, Peter Damm, Lene Ringholm Lancet Diab Endocrinol
  Treatment with faster aspart resulted in similar fetal growth and HbA1c, relative to insulin aspart, in women with type 1 or type 2 diabetes. Faster aspart can be used in women with type 1 or type 2 diabetes during pregnancy and post-delivery with no additional safety issues. (The Lancet Diabetes & Endocrinology 11, 11 (2023))
• 00:30
  [Series] Precision medicine of obesity as an integral part of type 2 diabetes management – past, present, and future - Lukasz Szczerbinski, Jose C Florez Lancet Diab Endocrinol
  Obesity is a complex and heterogeneous condition that leads to various metabolic complications, including type 2 diabetes. Unfortunately, for some, treatment options to date for obesity are insufficient, with many people not reaching sustained weight loss or having improvements in metabolic (...) (The Lancet Diabetes & Endocrinology 11, 11 (2023))
• 00:30
  [Series] Understanding diabetes heterogeneity: key steps towards precision medicine in diabetes - Richard David Leslie, Ronald Ching Wan Ma, Paul W Franks, Kristen J Nadeau, Ewan R Pearson, Maria Jose Redondo Lancet Diab Endocrinol
  Diabetes is a highly heterogeneous condition; yet, it is diagnosed by measuring a single blood-borne metabolite, glucose, irrespective of aetiology. Although pragmatically helpful, disease classification can become complex and limit advances in research and medical care. Here, we describe (...) (The Lancet Diabetes & Endocrinology 11, 11 (2023))
• 00:30
  [Series] Precision medicine for cardiometabolic disease: a framework for clinical translation - Paul W Franks, William T Cefalu, John Dennis, Jose C Florez, Chantal Mathieu, Robert W Morton, Martin Ridderstråle, Henrik H Sillesen, Coen D A Stehouwer Lancet Diab Endocrinol
  Cardiometabolic disease is a major threat to global health. Precision medicine has great potential to help to reduce the burden of this common and complex disease cluster, and to enhance contemporary evidence-based medicine. Its key pillars are diagnostics; prediction (of the primary disease); (...) (The Lancet Diabetes & Endocrinology 11, 11 (2023))
• 00:30
  [Corrections] Correction to Lancet Diabetes Endocrinol 2023; 11: 567–77 Lancet Diab Endocrinol
  Zhang L, Zhang Y, Shen S, et al. Safety and effectiveness of metformin plus lifestyle intervention compared with lifestyle intervention alone in preventing progression to diabetes in a Chinese population with impaired glucose regulation: a multicentre, open-label, randomised controlled trial. (...) (The Lancet Diabetes & Endocrinology 11, 11 (2023))
• 00:30
  [Comment] Faster and faster: meeting the challenges of delayed insulin action during pregnancy - Denice S Feig Lancet Diab Endocrinol
  Pregnant women with diabetes continue to have adverse pregnancy outcomes that are often related to hyperglycaemia.1 Tight glycaemic control has been recommended to reduce these adverse outcomes, but it is difficult to achieve these tight glycaemic targets. Part of the reason for this is the (...) (The Lancet Diabetes & Endocrinology 11, 11 (2023))

4 octobre

Lancet Diab Endocrinol https://www.thelancet.com/journals/landia/home

• 00:30
  [Comment] Time for changes in type 1 diabetes intervention trial designs - Mark A Atkinson, Michael J Haller, Desmond A Schatz, Manuela Battaglia, Chantal Mathieu Lancet Diab Endocrinol
  With the realisation that type 1 diabetes represents an autoimmune disorder, dozens of clinical trials have been performed over the past four decades aiming to preserve the metabolic function of the remaining insulin-producing islet ? cells in people recently diagnosed with the disorder.1 (...) (The Lancet Diabetes & Endocrinology 11, 11 (2023))

1er octobre

Lancet Diab Endocrinol https://www.thelancet.com/journals/landia/home

• 00:00
  [Editorial] What's in a decade? - The Lancet Diabetes & Endocrinology Lancet Diab Endocrinol
  September, 2023, marks the tenth anniversary of The Lancet Diabetes & Endocrinology. In our first editorial, we stated our commitment to “communicate the work and views that are essential to deliver effective public health measures and develop new treatments for endocrine disorders and (...) (The Lancet Diabetes & Endocrinology 11, 10 (2023))
• 00:00
  [In Focus] Alka Kanaya: representation in epidemiology - Talha Burki Lancet Diab Endocrinol
  Alka Kanaya emigrated to the USA with her parents and her younger brother in 1976, when she was six years old. It was the second migration for both her mother and her father; as children, they had fled what is now Pakistan during the unrest that accompanied Partition in 1947. After they (...) (The Lancet Diabetes & Endocrinology 11, 10 (2023))

29 septembre

Lancet Diab Endocrinol https://www.thelancet.com/journals/landia/home

• 00:30
  [Comment] Metastases to the thyroid gland: how does this affect cytohistological diagnoses? - Esther Diana Rossi, Liron Pantanowitz Lancet Diab Endocrinol
  Metastases to the thyroid gland can present a diagnostic challenge with respect to the cytological and histological evaluation of thyroid lesions. Data from the literature indicates that the rate of metastases to the thyroid gland ranges between 0% and 24% for patients with thyroid nodules in (...) (The Lancet Diabetes & Endocrinology 11, 11 (2023))

26 septembre

Lancet Diab Endocrinol https://www.thelancet.com/journals/landia/home

• 00:30
  [Articles] Mechanisms of weight loss-induced remission in people with prediabetes: a post-hoc analysis of the randomised, controlled, multicentre Prediabetes Lifestyle Intervention Study (PLIS) - Arvid Sandforth, Reiner Jumpertz von Schwartzenberg, Elsa Vazquez Arreola, Robert L Hanson, Gencer Sancar, Sarah Katzenstein, Karl Lange, Hubert Preißl, Simon I Dreher, Cora Weigert, Robert Wagner, Kostantinos Kantartzis, Jürgen Machann, Fritz Schick, Rainer Lehmann, Andreas Peter, Nikoletta Katsouli, Vasilis Ntziachristos, Corinna Dannecker, Louise Fritsche, Nikolaos Perakakis, Martin Heni, Peter Paul Nawroth, Stefan Kopf, Andreas F H Pfeiffer, Stefan Kabisch, Michael Stumvoll, Peter E H Schwarz, Hans Hauner, Andreas Lechner, Jochen Seissler, Iryna Yurchenko, Andrea Icks, Michele (…) Lancet Diab Endocrinol
  By contrast to remission of type 2 diabetes, resolution of prediabetes was characterised by an improvement in insulin sensitivity and reduced VAT. Because return to normal glucose regulation (NGR) prevents development of type 2 diabetes, we propose the concept of remission of prediabetes in (...) (The Lancet Diabetes & Endocrinology 11, 11 (2023))
• 00:30
  [Comment] Remission of prediabetes via lifestyle intervention - Michael Bergman, Brenda Dorcely Lancet Diab Endocrinol
  In this issue of The Lancet Diabetes & Endocrinology, a post-hoc analysis of the Prediabetes Lifestyle Intervention Study (PLIS) by Sandforth and colleagues1 provides insights into the physiological mechanisms that govern remission to normal glucose regulation (NGR) from prediabetes. (...) (The Lancet Diabetes & Endocrinology 11, 11 (2023))

12 septembre

Lancet Diab Endocrinol https://www.thelancet.com/journals/landia/home

• 00:30
  [Review] Current insights and emerging trends in early-onset type 2 diabetes - Shivani Misra, Calvin Ke, Shylaja Srinivasan, Alpesh Goyal, Moffat J Nyriyenda, Jose C Florez, Kamlesh Khunti, Dianna J Magliano, Andrea Luk Lancet Diab Endocrinol
  Type 2 diabetes diagnosed in childhood or early adulthood is termed early-onset type 2 diabetes. Cases of early-onset type 2 diabetes are increasing rapidly globally, alongside rising obesity. Compared with a diagnosis later in life, an earlier-onset diagnosis carries an unexplained excess (...) (The Lancet Diabetes & Endocrinology 11, 10 (2023))
• 00:30
  [Articles] Life expectancy associated with different ages at diagnosis of type 2 diabetes in high-income countries: 23 million person-years of observation - Emerging Risk Factors Collaboration Lancet Diab Endocrinol
  Every decade of earlier diagnosis of diabetes was associated with about 3–4 years of lower life expectancy, highlighting the need to develop and implement interventions that prevent or delay the onset of diabetes and to intensify the treatment of risk factors among young adults diagnosed with (...) (The Lancet Diabetes & Endocrinology 11, 10 (2023))
• 00:30
  [Comment] Many years of life lost to young-onset type 2 diabetes - Bruce B Duncan, Maria Inês Schmidt Lancet Diab Endocrinol
  Years of life lost to diabetes is a metric that is receiving increasing attention given its potential use in health education and advocacy. People with diabetes have a loss of life expectancy of between 2·5 years and 12·9 years over the lifespan, as shown in multiple high-income populations.1 (The Lancet Diabetes & Endocrinology 11, 10 (2023))

9 septembre

Lancet Diab Endocrinol https://www.thelancet.com/journals/landia/home

• 00:30
  [Articles] The optimal healthy ranges of thyroid function defined by the risk of cardiovascular disease and mortality: systematic review and individual participant data meta-analysis - Yanning Xu, Arash Derakhshan, Ola Hysaj, Lea Wildisen, Till Ittermann, Alessandro Pingitore, Nazanin Abolhassani, Marco Medici, Lambertus A L M Kiemeney, Niels P Riksen, Robin P F Dullaart, Stella Trompet, Marcus Dörr, Suzanne J Brown, Börge Schmidt, Dagmar Führer-Sakel, Mark P J Vanderpump, Axel Muendlein, Heinz Drexel, Howard A Fink, M Kamran Ikram, Maryam Kavousi, Connie M Rhee, Isabela M Bensenor, Fereidoun Azizi, Graeme J Hankey, Massimo Iacoviello, Misa Imaizumi, Graziano Ceresini, Luigi Ferrucci, José A Sgarbi, Douglas C Bauer, Nick Wareham, Kristien Boelaert, Stephan J L Bakker, J (…) Lancet Diab Endocrinol
  There was a J-shaped association of FT4 with cardiovascular disease and mortality. Low concentrations of TSH were associated with a higher risk of all-cause mortality and cardiovascular disease mortality. The 20–40th percentiles of FT4 and the 60–80th percentiles of TSH could represent the (...) (The Lancet Diabetes & Endocrinology 11, 10 (2023))
• 00:30
  [Comment] Is it time to re-assess the development of thyroid function reference ranges? - Elizabeth N Pearce Lancet Diab Endocrinol
  Because thyroid dysfunction symptoms are non-specific,1 the diagnosis and management of thyroid disorders relies heavily on serum thyroid function testing. Current thyroid function test reference ranges are defined based on the 2·5–97·5th percentiles for laboratory values assessed in healthy (...) (The Lancet Diabetes & Endocrinology 11, 10 (2023))

6 septembre

Lancet Diab Endocrinol https://www.thelancet.com/journals/landia/home

• 00:30
  [Correspondence] Craniopharyngioma: medico-social support for optimised care - Thomas Cuny, Rachel Reynaud, Pascal Barat, Blandine Gatta-Cherifi Lancet Diab Endocrinol
  Craniopharyngioma represents the archetypal pathology requiring multidisciplinary and transitional approaches, and for which the post-treatment management is as important, if not more so, than the treatment of the tumour itself.1 Recent progress made in the understanding of the pathogenesis of (...) (The Lancet Diabetes & Endocrinology 11, 10 (2023))

2 septembre

Lancet Diab Endocrinol https://www.thelancet.com/journals/landia/home

• 00:30
  [Review] Maternal type 1 diabetes and relative protection against offspring transmission - Lowri A Allen, Peter N Taylor, Kathleen M Gillespie, Richard A Oram, Colin M Dayan Lancet Diab Endocrinol
  Type 1 diabetes is around twice as common in the offspring of men with type 1 diabetes than in the offspring of women with type 1 diabetes, but the reasons for this difference are unclear. This Review summarises the evidence on the rate of transmission of type 1 diabetes to the offspring of (...) (The Lancet Diabetes & Endocrinology 11, 10 (2023))

1er septembre

Lancet Diab Endocrinol https://www.thelancet.com/journals/landia/home

• 00:30
  [Comment] The TRAVERSE trial: cardiovascular safety of testosterone therapy for older men - Bradley D Anawalt Lancet Diab Endocrinol
  For decades, there has been controversy about whether testosterone therapy has deleterious effects on the risk of major cardiovascular events in older men. As the number of prescriptions for testosterone therapy has escalated, this controversy has heightened.1 Although some epidemiological (...) (The Lancet Diabetes & Endocrinology 11, 10 (2023))
• 00:00
  [Corrections] Correction to Lancet Diabetes Endocrinol 2023; 11: 402–13 Lancet Diab Endocrinol
  Medas F, Dobrinja C, Al-Suhaimi EA, et al. Effect of the COVID-19 pandemic on surgery for indeterminate thyroid nodules (THYCOVID): a retrospective, international, multicentre, cross-sectional study. Lancet Diabetes Endocrinol 2023; 11: 402–13—In this Article, the order of author François (...) (The Lancet Diabetes & Endocrinology 11, 9 (2023))
• 00:00
  [Correspondence] Tuning of cellular insulin release by music for real-time diabetes control - Haijie Zhao, Shuai Xue, Marie-Didiée Hussherr, Peter Buchmann, Ana Palma Teixeira, Martin Fussenegger Lancet Diab Endocrinol
  Music consists of acoustic waves that are converted by the bony ossicles in the middle ear into mechanical vibrations. These vibrations activate mechanosensitive ion channels in hair cells,1 causing membrane depolarisation and release of neurotransmitters, thereby influencing human emotion. (...) (The Lancet Diabetes & Endocrinology 11, 9 (2023))
• 00:00
  [In Focus] Carmella Evans-Molina: being of service - Talha Burki Lancet Diab Endocrinol
  A lot of people never leave West Virginia. The landscape is breathtaking: lush green mountains bisected by all manner of creeks, rivers, and streams. There is a close sense of community, forged in part by decade upon decade of coal mining. But West Virginia is also one of the poorest states in (...) (The Lancet Diabetes & Endocrinology 11, 9 (2023))
• 00:00
  [Comment] Built environment and obesity prevention research: moving from niche to norm - Deborah Salvo, Maura Kepper, Ruth Hunter, Alejandra Jáuregui Lancet Diab Endocrinol
  Physical inactivity and unhealthy eating are considered the primary modifiable risk factors for obesity (ie, obesity-related behaviours). Despite a large body of evidence showing the important role of the built environment in active living, healthy eating, and obesity prevention, research on (...) (The Lancet Diabetes & Endocrinology 11, 9 (2023))

29 août

Lancet Diab Endocrinol https://www.thelancet.com/journals/landia/home

• 00:30
  [Comment] Call for prospective studies of continuous glucose monitoring to define the glycaemic response to bariatric surgery - Lia Bally, Bernard Khoo, Filip Knop, Sten Madsbad, Mary-Elizabeth Patti, Tricia Tan Lancet Diab Endocrinol
  During the past decade, there has been an increase in the use of continuous glucose monitoring (CGM) technology in clinical practice1 and in clinical trials and research2 for diabetes. Three main factors have led to this increase. First, advances in CGM technology have improved the accuracy of (...) (The Lancet Diabetes & Endocrinology 11, 10 (2023))

22 août

Lancet Diab Endocrinol https://www.thelancet.com/journals/landia/home

• 00:30
  [Articles] Adjuvant mitotane versus surveillance in low-grade, localised adrenocortical carcinoma (ADIUVO): an international, multicentre, open-label, randomised, phase 3 trial and observational study - Massimo Terzolo, Martin Fassnacht, Paola Perotti, Rossella Libé, Darko Kastelan, André Lacroix, Wiebke Arlt, Harm Reinout Haak, Paola Loli, Bénédicte Decoudier, Helene Lasolle, Marcus Quinkler, Magalie Haissaguerre, Olivier Chabre, Philippe Caron, Antonio Stigliano, Roberta Giordano, Maria Chiara Zatelli, Irina Bancos, Maria Candida Barisson Villares Fragoso, Letizia Canu, Michaela Luconi, Soraya Puglisi, Vittoria Basile, Giuseppe Reimondo, Matthias Kroiss, Felix Megerle, Stefanie Hahner, Otilia Kimpel, Tina Dusek, Svenja Nölting, Isabelle Bourdeau, Vasileios Chortis, Madeleine Hester (…) Lancet Diab Endocrinol
  Adjuvant mitotane might not be indicated in patients with low-grade, localised adrenocortical carcinoma considering the relatively good prognosis of these patients, and no significant improvement in recurrence-free survival and treatment-associated toxicity in the mitotane group. However, the (...) (The Lancet Diabetes & Endocrinology 11, 10 (2023))
• 00:30
  [Comment] Good news for patients with adrenocortical carcinoma from the ADIUVO trial - Martin Reincke Lancet Diab Endocrinol
  Recently, a man aged 50 years came to my office. He had received surgery for a right-sided non-functional adrenocortical carcinoma measuring 11 cm in diameter and had been referred to discuss adjuvant treatment. Based on adrenal histology findings, he had a European Network for the Study of (...) (The Lancet Diabetes & Endocrinology 11, 10 (2023))

11 août

Lancet Diab Endocrinol https://www.thelancet.com/journals/landia/home

• 00:30
  [Editorial] Eating disorders: care not keeping up with demand - The Lancet Diabetes & Endocrinology Lancet Diab Endocrinol
  Eating disorders are complex mental health conditions that affect an estimated 1·25 million people in the UK, three quarters of whom are female. The disorders often emerge during adolescence and include anorexia nervosa, bulimia nervosa, binge-eating disorder, avoidant or restrictive food (...) (The Lancet Diabetes & Endocrinology 11, 9 (2023))

8 août

Lancet Diab Endocrinol https://www.thelancet.com/journals/landia/home

• 00:30
  [Corrections] Correction to Lancet Diabetes Endocrinol 2023; 11: 490–508 Lancet Diab Endocrinol
  Benhalima K, Beunen K, Siegelaar SE, et al. Management of type 1 diabetes in pregnancy: update on lifestyle, pharmacological treatment, and novel technologies for achieving glycaemic targets. Lancet Diabetes Endocrinol 2023; 11: 490–508—In this Review, in table 1 on page 496, the specific (...) (The Lancet Diabetes & Endocrinology 11, 10 (2023))

5 août

Lancet Diab Endocrinol https://www.thelancet.com/journals/landia/home

• 00:30
  [Review] National UK guidelines for the management of paediatric craniopharyngioma - Hoong-Wei Gan, Paul Morillon, Assunta Albanese, Kristian Aquilina, Chris Chandler, Yen-Ching Chang, Evangelos Drimtzias, Sarah Farndon, Thomas S Jacques, Márta Korbonits, Adam Kuczynski, Jennifer Limond, Louise Robinson, Ian Simmons, Nick Thomas, Sophie Thomas, Nicola Thorp, Faraneh Vargha-Khadem, Daniel Warren, Bassel Zebian, Conor Mallucci, Helen Alexandra Spoudeas Lancet Diab Endocrinol
  Although rare, craniopharyngiomas constitute up to 80% of tumours in the hypothalamic–pituitary region in childhood. Despite being benign, the close proximity of these tumours to the visual pathways, hypothalamus, and pituitary gland means that both treatment of the tumour and the tumour (...) (The Lancet Diabetes & Endocrinology 11, 9 (2023))

1er août

Lancet Diab Endocrinol https://www.thelancet.com/journals/landia/home

• 00:30
  [Correspondence] Achieving replicable subphenotypes of adult-onset diabetes - Jithin Sam Varghese, Rodrigo M Carrillo-Larco, KM Venkat Narayan Lancet Diab Endocrinol
  In The Lancet Diabetes & Endocrinology, Norbert Stefan and Matthias Schulze addressed the strengths, limitations, and opportunities of metabolic subphenotypes (data-driven clusters), relative to the widely accepted risk prediction models and stratification of cardiometabolic disease.1 The (...) (The Lancet Diabetes & Endocrinology 11, 9 (2023))
• 00:30
  [Correspondence] Achieving replicable subphenotypes of adult-onset diabetes – Authors' reply - Norbert Stefan, Matthias B Schulze Lancet Diab Endocrinol
  We thank Jithin Sam Varghese and colleagues for their comments on our Review.1 They raise an important question on the extent to which metabolic subphenotypes identified in a specific population and, more importantly, in a population with a specific ethnic background can be replicated in other (...) (The Lancet Diabetes & Endocrinology 11, 9 (2023))
• 00:00
  [Country Focus] Addressing health and demographic challenges in Japan's ageing society - Eri Toda Kato, Junko Sato Lancet Diab Endocrinol
  Japan is internationally recognised as a leading example of an ageing society with its population starting to decline since 2008, primarily attributed to a low fertility rate. The proportion of individuals older than 65 years has undergone a five-fold surge from 6% in 1960 to 29% in 2020, the (...) (The Lancet Diabetes & Endocrinology 11, 8 (2023))
• 00:00
  [Correspondence] There is no magic bullet for obesity - Ildiko Lingvay, Priya Sumithran, Carel W le Roux, Ricardo V Cohen Lancet Diab Endocrinol
  Treating obesity has wide-ranging benefits on health and wellbeing.1 Advances in medications for obesity have sparked interest, and excessive unregulated media attention has driven unprecedented demand for these new agents. However, the media coverage risks propagating the view that there is a (...) (The Lancet Diabetes & Endocrinology 11, 8 (2023))

29 juillet

Lancet Diab Endocrinol https://www.thelancet.com/journals/landia/home

• 00:30
  [Review] Mechanisms and clinical relevance of the bidirectional relationship of viral infections with metabolic diseases - Nikolaos Perakakis, Hani Harb, Benjamin G Hale, Zsuzsanna Varga, Charlotte Steenblock, Waldemar Kanczkowski, Vasileia Ismini Alexaki, Barbara Ludwig, Peter Mirtschink, Michele Solimena, Nicole Toepfner, Sebastian Zeissig, Manuel Gado, Irene Alma Abela, Felix Beuschlein, Giatgen A Spinas, Claudia Cavelti-Weder, Philipp A Gerber, Michael Huber, Alexandra Trkola, Milo A Puhan, Wendy Wei-Lynn Wong, Andreas Linkermann, Viswanathan Mohan, Hendrik Lehnert, Peter Nawroth, Triantafyllos Chavakis, Geltrude Mingrone, Christian Wolfrum, Annelies S Zinkernagel, Stefan R Bornstein Lancet Diab Endocrinol
  Viruses have been present during all evolutionary steps on earth and have had a major effect on human history. Viral infections are still among the leading causes of death. Another public health concern is the increase of non-communicable metabolic diseases in the last four decades. In this (...) (The Lancet Diabetes & Endocrinology 11, 9 (2023))

25 juillet

Lancet Diab Endocrinol https://www.thelancet.com/journals/landia/home

• 00:30
  [Articles] Comparative effectiveness of SGLT2 inhibitors, GLP-1 receptor agonists, DPP-4 inhibitors, and sulfonylureas on risk of major adverse cardiovascular events: emulation of a randomised target trial using electronic health records - Yan Xie, Benjamin Bowe, Hong Xian, Travis Loux, Janet B McGill, Ziyad Al-Aly Lancet Diab Endocrinol
  Both SGLT2 inhibitors and GLP-1 receptor agonists were associated with reduced risk of MACE compared with DPP-4 inhibitors or sulfonylureas. DPP-4 inhibitors were associated with reduced risk of MACE compared with sulfonylureas. There was no statistically significant difference in risk of MACE (...) (The Lancet Diabetes & Endocrinology 11, 9 (2023))
• 00:30
  [Comment] Pragmatic trials, a step forward to assess cardiovascular efficacy of new glucose-lowering agents - André J Scheen Lancet Diab Endocrinol
  Cardiovascular disease represents a major burden in people with type 2 diabetes, and the prevention of cardiovascular complications has become a main objective when treating at-risk people. Numerous cardiovascular outcome trials (CVOTs) were published in recent years that showed not only the (...) (The Lancet Diabetes & Endocrinology 11, 9 (2023))

22 juillet

Lancet Diab Endocrinol https://www.thelancet.com/journals/landia/home

• 00:30
  [Articles] Lipoprotein(a) and carotid intima-media thickness in children with familial hypercholesterolaemia in the Netherlands: a 20-year follow-up study - Lotte M de Boer, Albert Wiegman, Jeffrey Kroon, Sotirios Tsimikas, Calvin Yeang, Merel C Peletier, Alma Revers, John J P Kastelein, Aeilko H Zwinderman, Barbara A Hutten Lancet Diab Endocrinol
  Our findings suggest that lipoprotein(a) concentrations contribute significantly to arterial wall thickening in children with familial hypercholesterolaemia who were followed-up until adulthood, suggesting that lipoprotein(a) is an independent and additional risk factor for early (...) (The Lancet Diabetes & Endocrinology 11, 9 (2023))
• 00:30
  [Comment] Lipoprotein(a) and subclinical vascular disease progression in children with familial hypercholesterolaemia - Raul D Santos Lancet Diab Endocrinol
  Lipoprotein(a) is a cholesterol-rich particle, high concentrations of which are associated with a greater risk of atherosclerosis and occurrence of aortic valve calcification in the general population.1 This might also be the case for adults affected by familial hypercholesterolaemia,2 a (...) (The Lancet Diabetes & Endocrinology 11, 9 (2023))

18 juillet

Lancet Diab Endocrinol https://www.thelancet.com/journals/landia/home

• 00:30
  [Articles] Cardiovascular morbidity and mortality in patients in Wales, UK with resistance to thyroid hormone ? (RTH?): a linked-record cohort study - Onyebuchi E Okosieme, Danyal Usman, Peter N Taylor, Colin M Dayan, Greta Lyons, Carla Moran, Krishna Chatterjee, Dafydd Aled Rees Lancet Diab Endocrinol
  We have documented reduced survival and increased cardiovascular morbidity in a cohort of patients with RTH? for the first time. These outcomes might be driven by lifelong cardiac exposure to thyroid hormone excess; and effective therapies, targeting hormone resistant pathways, could (...) (The Lancet Diabetes & Endocrinology 11, 9 (2023))
• 00:30
  [Comment] Increased cardiovascular morbidity and mortality in patients with resistance to thyroid hormone - Samuel Refetoff, Luca Persani, W Edward Visser Lancet Diab Endocrinol
  The main actions of thyroid hormone are induced through binding of the bioactive hormone T3 to nuclear thyroid hormone receptors (TRs).1 There are two receptor types, encoded by the genes THRA and THRB, with differing tissue expressions. TR?1 is primarily expressed in the heart, bone, (...) (The Lancet Diabetes & Endocrinology 11, 9 (2023))

15 juillet

Lancet Diab Endocrinol https://www.thelancet.com/journals/landia/home

• 00:30
  [Country Focus] Obesity in the USA: diet and lifestyle key to prevention - Frank B Hu Lancet Diab Endocrinol
  The obesity epidemic in the USA continues to escalate, posing a significant public health crisis. According to the National Health and Nutrition Examination Survey, the prevalence of adult obesity (BMI ?30·0 kg/m2) increased from 30·5% in 2000 to 41·9% in 2020. During the same time, the (...) (The Lancet Diabetes & Endocrinology 11, 9 (2023))

14 juillet

Lancet Diab Endocrinol https://www.thelancet.com/journals/landia/home

• 00:30
  [Comment] Expression of Concern—Estimating dose-response relationships for vitamin D with coronary heart disease, stroke, and all-cause mortality: observational and Mendelian randomisation analyses - Editors of The Lancet Diabetes & Endocrinology Lancet Diab Endocrinol
  On Oct 27, 2021, The Lancet Diabetes & Endocrinology published the Article, “Estimating dose-response relationships for vitamin D with coronary heart disease, stroke, and all-cause mortality: observational and Mendelian randomisation analyses”.1 On Nov 30, 2022, the editors of The Lancet (...) (The Lancet Diabetes & Endocrinology 11, 9 (2023))

13 juillet

Lancet Diab Endocrinol https://www.thelancet.com/journals/landia/home

• 00:30
  [In Focus] Peerzada Ovais Ahmad: a quest to save lives - Apoorva Gomber, Marta Koch Lancet Diab Endocrinol
  Peerzada Ovais Ahmad never wanted to become a doctor. But growing up in the serendipitous valleys of Kashmir and pursuing a Bachelor's degree in science drew him to explore medical school in Bangladesh, where he fell in love with endocrinology and the complexities of hormones. Ovais remembers (...) (The Lancet Diabetes & Endocrinology 11, 8 (2023))
• 00:30
  [Editorial] Banning diabetes blanket bans - The Lancet Diabetes & Endocrinology Lancet Diab Endocrinol
  With effective management, there is no reason why people with diabetes would not be able successfully perform any job or occupation. However, certain job roles and employers have a blanket ban for people with the condition, particularly those who require insulin. This is often the case in (...) (The Lancet Diabetes & Endocrinology 11, 8 (2023))

11 juillet

Lancet Diab Endocrinol https://www.thelancet.com/journals/landia/home

• 10:42
  [Editorial] Gender equality: timely and timeless - The Lancet Diabetes & Endocrinology Lancet Diab Endocrinol
  With an estimated global population of around 8 billion people, the world's population continues to grow steadily. Increased life expectancy has resulted in a trend in the distribution of populations worldwide towards older age. For instance, in Japan, nearly 30% of the population was aged 65 (...) (The Lancet Diabetes & Endocrinology 11, 8 (2023))

8 juillet

Lancet Diab Endocrinol https://www.thelancet.com/journals/landia/home

• 00:30
  [Review] Diagnostic challenges in cyclic Cushing's syndrome: a systematic review - Elisabeth Nowak, Frederick Vogel, Adriana Albani, Leah Braun, German Rubinstein, Stephanie Zopp, Katrin Ritzel, Felix Beuschlein, Marily Theodoropoulou, Martin Reincke Lancet Diab Endocrinol
  Cyclic Cushing's syndrome is a subentity of Cushing's syndrome in which phases of biochemical hypercortisolism (peaks) are followed by spontaneous periods of physiological or even hypocortisolaemic cortisol secretion (troughs). To identify common features of cyclic Cushing's syndrome, we (...) (The Lancet Diabetes & Endocrinology 11, 8 (2023))

6 juillet

Lancet Diab Endocrinol https://www.thelancet.com/journals/landia/home

• 00:30
  [Corrections] Correction to Lancet Diabetes Endocrinol 2023; 11: 86–95 Lancet Diab Endocrinol
  Mathiesen ER, Alibegovic AC, Corcoy R, et al. Insulin degludec versus insulin detemir, both in combination with insulin aspart, in the treatment of pregnant women with type 1 diabetes (EXPECT): an open?label, multinational, randomised, controlled, non-inferiority trial. Lancet Diabetes (...) (The Lancet Diabetes & Endocrinology 11, 8 (2023))

4 juillet

Lancet Diab Endocrinol https://www.thelancet.com/journals/landia/home

• 00:30
  [Articles] Safety and effectiveness of metformin plus lifestyle intervention compared with lifestyle intervention alone in preventing progression to diabetes in a Chinese population with impaired glucose regulation: a multicentre, open-label, randomised controlled trial - Lihui Zhang, Yunliang Zhang, Sheng'ai Shen, Xueying Wang, Luling Dong, Qiuyun Li, Weidong Ren, Yufeng Li, Jianling Bai, Qiuhong Gong, Hongyu Kuang, Lin Qi, Qiang Lu, Wenli Cheng, Yanjie Liu, Shuang Yan, Donghong Wu, Hui Fang, Fang Hou, Yingju Wang, Zhixia Yang, Xu Lian, Jianling Du, Ningling Sun, Linong Ji, Guangwei Li, China Diabetes Prevention Program Study Group Lancet Diab Endocrinol
  Metformin plus lifestyle intervention further reduced the risk of developing diabetes than lifestyle intervention alone in Chinese people with impaired glucose regulation, showing additional benefits of combined intervention in preventing progression to diabetes without new safety concerns. (The Lancet Diabetes & Endocrinology 11, 8 (2023))
• 00:30
  [Comment] Prediabetes: never too early to intervene - Clifford J Bailey Lancet Diab Endocrinol
  A diagnosis of type 2 diabetes is usually preceded by several years of impaired glucose regulation referred to as prediabetes or intermediate hyperglycaemia. Prediabetes is variously defined by different organisations as an HbA1c of 5·7–6·4% (39–47 mmol/mol) or 6·0–6·4% (42–47 mmol/mol), and (...) (The Lancet Diabetes & Endocrinology 11, 8 (2023))
• 00:30
  [Articles] Patient-reported outcomes, weight loss, and remission of type 2 diabetes 3 years after gastric bypass and sleeve gastrectomy (Oseberg); a single-centre, randomised controlled trial - Marius Svanevik, Jolanta Lorentzen, Heidi Borgeraas, Rune Sandbu, Birgitte Seip, Asle W Medhus, Jens K Hertel, Ronette L Kolotkin, Milada C Småstuen, Dag Hofsø, Jøran Hjelmesæth Lancet Diab Endocrinol
  At 3 years, gastric bypass was superior to sleeve gastrectomy in patients with type 2 diabetes and obesity regarding weight related quality of life, reflux symptoms, weight loss, and remission of diabetes, while symptoms of abdominal pain, indigestion, diarrhoea, dumping, depression and binge (...) (The Lancet Diabetes & Endocrinology 11, 8 (2023))
• 00:30
  [Comment] Patient-reported outcome measures after metabolic surgery - Geltrude Mingrone, Lidia Castagneto-Gissey, Stefan R Bornstein Lancet Diab Endocrinol
  More than 1 billion people worldwide live with obesity, a prevalence that is expected to double by 2035. Type 2 diabetes and obesity are strictly interconnected, with almost 80% of people affected by type 2 diabetes having also obesity.1 (The Lancet Diabetes & Endocrinology 11, 8 (2023))

28 juin

Lancet Diab Endocrinol https://www.thelancet.com/journals/landia/home

• 00:30
  [Articles] Enteroviruses and risk of islet autoimmunity or type 1 diabetes: systematic review and meta-analysis of controlled observational studies detecting viral nucleic acids and proteins - Sonia R Isaacs, Anju Roy, Brieana Dance, Emily J Ward, Dylan B Foskett, Anna J Maxwell, William D Rawlinson, Ki Wook Kim, Maria E Craig Lancet Diab Endocrinol
  These findings highlight the association between enteroviruses and islet autoimmunity or type 1 diabetes. Our data strengthen the rationale for vaccine development targeting diabetogenic enterovirus types, particularly those within Enterovirus B. Prospective studies of early life are needed to (...) (The Lancet Diabetes & Endocrinology 11, 8 (2023))
• 00:30
  [Comment] Islet autoimmunity and type 1 diabetes associated with enterovirus infections - Antonio Toniolo Lancet Diab Endocrinol
  Although it is reasonable for physicians to be sceptical of new ideas, innovation often emerges from situations in which results carefully obtained do not fit within the accepted paradigms.1 (The Lancet Diabetes & Endocrinology 11, 8 (2023))
• 00:30
  [Comment] Sleep and cardiometabolic health—not so strange bedfellows - Shahrad Taheri Lancet Diab Endocrinol
  “Sleep dwell upon thine eyes, peace in thy breast.” Romeo and Juliet (Act 2, Scene 2), William Shakespeare (1597) (The Lancet Diabetes & Endocrinology 11, 8 (2023))

27 juin

Lancet Diab Endocrinol https://www.thelancet.com/journals/landia/home

• 00:30
  [Review] Predicting and preventing heart failure in type 2 diabetes - Ambarish Pandey, Muhammad Shahzeb Khan, Kershaw V Patel, Deepak L Bhatt, Subodh Verma Lancet Diab Endocrinol
  The burden of heart failure among people with type 2 diabetes is increasing globally. People with comorbid type 2 diabetes and heart failure often have worse outcomes than those with only one of these conditions—eg, higher hospitalisation and mortality rates. Therefore, it is essential to (...) (The Lancet Diabetes & Endocrinology 11, 8 (2023))
• 00:30
  [Comment] Behind the scenes: epigenetic mechanisms rule the roost in pubertal timing - Ravikumar Balasubramanian Lancet Diab Endocrinol
  In humans, following a mysterious quiescence during childhood, the reactivation of pulsatile secretion of gonadotropin-releasing hormone (GnRH) from the hypothalamus marks the onset of puberty.1 The precise molecular triggers that govern this dynamic developmental transition remain elusive. (...) (The Lancet Diabetes & Endocrinology 11, 8 (2023))
• 00:30
  [Comment] Managing type 2 diabetes needs a paradigm change - K M Venkat Narayan, Ram Jagannathan, Martin Ridderstråle Lancet Diab Endocrinol
  We are at the threshold of a transformative revolution in medicine and public health, propelled by breakthroughs in molecular biology and informatics, alongside a deeper comprehension of complex heterogeneous manifestations of diseases. These advancements embrace the vast spectrum of (...) (The Lancet Diabetes & Endocrinology 11, 8 (2023))
• 00:30
  [Articles] Rare variants in the MECP2 gene in girls with central precocious puberty: a translational cohort study - Ana P M Canton, Flávia R Tinano, Leonardo Guasti, Luciana R Montenegro, Fiona Ryan, Deborah Shears, Maria Edna de Melo, Larissa G Gomes, Mariana P Piana, Raja Brauner, Rafael Espino-Aguilar, Arancha Escribano-Muñoz, Alyssa Paganoni, Jordan E Read, Márta Korbonits, Carlos E Seraphim, Silvia S Costa, Ana Cristina Krepischi, Alexander A L Jorge, Alessia David, Lena R Kaisinger, Ken K Ong, John R B Perry, Ana Paula Abreu, Ursula B Kaiser, Jesús Argente, Berenice B Mendonca, Vinicius N Brito, Sasha R Howard, Ana Claudia Latronico Lancet Diab Endocrinol
  We identified rare MECP2 variants in girls with central precocious puberty, with or without mild neurodevelopmental abnormalities. MECP2 might have a role in the hypothalamic control of human pubertal timing, adding to the evidence of involvement of epigenetic and genetic mechanisms in this (...) (The Lancet Diabetes & Endocrinology 11, 8 (2023))